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Prostate cancer is the most common cancer occurring in males.  The identification 
of novel microRNAs (miRs) that contribute to tumor progression represents prospective 
treatment targets.  miRs are small non-coding RNAs important in gene regulation with 
specific tissue expression patterns.  Each miR is thought to affect the expression of 
hundreds of different RNA targets.  Two putative oncomiRs, miR-155 and miR-146a, 
were shown to be differentially expressed in the human derived, prostate cell sublines 
M12 and F6.  Quantification of endogenous miR expression showed high levels in the 
metastatic M12 cell line versus low in its weakly tumorigenic F6 variant.  The restoration 
xi 
of miR expression to M12 levels was evaluated on F6 growth, morphology, and in vitro 
behavior.  F6 plus miR-155 or miR-146a displayed increased growth, motility and 
invasiveness when compared to M12, with less organized structural morphology when 
grown embedded in matrigel.  Altogether these results suggest that the overexpression of 
miRs 155 and 146a could contribute to tumor progression in vivo. 
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INTRODUCTION 
 
Prostate Function and Structure 
The prostate is an accessory reproductive organ within the male urogenital system 
composed of many acini that lead into ductules, which together function to create an 
exocrine gland.  The male urethra is completely encircled by the prostate and serves as a 
receptacle repository for prostate epithelial secretions, such as prostate specific antigen 
(PSA), spermine, proteases, and others.  Although the prostate gland is secretory, only a 
small portion of the gland has exocrine capabilities.  The major cell types that form the 
prostate gland are found within the highly proliferative epithelium.  The epithelium is 
known to contribute to the medical pathologies of benign prostate hypertrophy (BPH), 
proliferative inflammatory atrophy (PIA), prostatic intraepithelial neoplasm (PIN), and 
prostate carcinoma (PCa) (1).  The prostate epithelium is composed of a layer of luminal 
cells and a layer of basal cells immersed within mesenchymal stromal cells (1-3).  These 
two epithelial cells have distinct functions, localization, and morphological differences 
(4).  The luminal cells are tall columnar cells that line the ductal lumen (1, 2), produce 
exocrine secretions such as PSA and prostatic acid phosphatase (PAP), express androgen 
receptor and keratins (K) 8 and 18, and are differentiated with a high apoptotic index (3, 
5).  Basal cells are stretched cubiodal cells found juxtaposed between the luminal cells 
and the basement membrane (2), are further characterized by the expression of K5, 14, 
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and 18, an absence of PSA, PAP, androgen receptor, and are undifferentiated with a high 
proliferative capacity (3, 5).  Neuroendocrine cells can be found dispersed throughout the 
prostate epithelium releasing paracrine secretions of neuropeptides and hormones to 
potentially modulate proliferation and differentiation of exocrine cells (2, 5).    
The developing prostate is marked by an androgen dependent mesenchymal-stromal 
maturation, which contributes to the differentiation and development of the epithelium.  
The secretion of androgen by stromal cells allows subpopulations of cells containing 
androgen receptor to further differentiate into luminal cells.  The prostate is considered an 
androgen dependent organ, but contains a heterogeneous mixture of undifferentiated 
epithelial cells that do not express androgen receptors (i.e. basal) and differentiated 
epithelial cells (i.e. luminal) and the mesenchyme that do express high levels of androgen 
receptor.  All cells within the epithelium begin androgen receptor negative until 
differentiation allows the expression of androgen receptor in luminal cells.  In addition to 
the normal androgen receptor expression during maturation, the androgen receptor has 
been found to have a higher and more heterogeneous expression throughout the luminal 
and stromal cells during prostate hypertrophy and malignancy states (1).    The 
mesenchymal stromal cells also influence the development of the prostate epithelium 
through the secretion of various factors (2, 6), such as epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α), insulin growth factors (IGF), and fibroblast 
growth factor (FGF) (2).  These factors interact in a paracrine fashion with epithelial cells 
leading to glandular and ductal development and continued proliferation (2, 5).  In return, 
the differentiated epithelium acts in a cell-to-cell manner with mesenchymal smooth 
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muscle cells inducing their differentiation and morphological sheet structure.  Therefore, 
the overall development of the prostate is due to the androgen dependent mesenchyme 
interacting with the semi-androgen and growth factor-dependent epithelium in a paracrine 
loop. 
The differentiation of cells within the epithelium has led to the discovery of two 
additional cell populations, the intermediate transitional cells, based on keratin express.  
As previously noted, basal cells expression high levels of K5, K14, and moderate levels 
of K18 and luminal cells express high levels of K8 and K18.  The first intermediate 
transitional cell is the intermediate basal cell expressing high levels of K5 and K18, no 
K14, and resides within the basal epithelial compartment juxtaposed to the luminal cells.  
The second intermediate transitional cell is the intermediate luminal cell expressing 
moderate levels of K5, high levels of K18, and resides juxtaposed to basal compartment 
(2, 4).  In addition, there has been positive antibody labeling of the neuroendocrine cells 
showing a presence of K5 and K14, indicating both luminal exocrine and neuroendocrine 
cells are potentially derived from the same intermediate cell lineage (2, 5).   
The origin of the prostate epithelium has been postulated to originate from a stem cell 
that behaves like other epithelial stem cells (i.e. intestinal) and undergo asymmetrical 
division to create an undifferentiated stem cell and a differentiated progenitor cell (2, 4, 
5).    Due to the high proliferative capacity and undifferentiation of basal cells, along with 
an overabundance of their intermediate cells during neonatal, perinatal, and postnatal 
development (5), it is believed that the prostate epithelium stem cells are found within the 
basal cell compartment (2, 4), although there have been no direct markers for this 
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putative stem cell (3).  Thus, it has been theorized that the prostate itself begins with a 
basal stem cell that proliferates and differentiates through intermediate cell lineages to 
create basal cells and differentiated exocrine luminal cells and neuroendocrine cells, in 
the presence of mesenchymal-stromal influences (2, 4, 5). 
The prostate gland contains three distinct histological glandular zones: the transitional 
(5%-10%, bilateral to the urethra), central (20%-25%, surrounding the ejaculatory ducts), 
and the peripheral (70%-75%, lateral aspects of the gland).  The transitional zone, 
although composing the smallest amount of the gland, is unique in its likelihood for 
continued growth throughout life, the process seen with BPH.  The central zone has 
larger acini, more complex ductal branching and sac-like formations, and dense stroma, 
whereas the peripheral zone has smaller acini, less complex ductal branching, and loose 
stroma.  The peripheral zone accounts for most prostatic carcinomas and inflammation, 
whereas the central zone is only responsible for approximately 5% of carcinomas (1). 
 
Pathology of Prostate Carcinoma 
Prostate cancer is the top diagnosed cancer in males within the United States, with the 
second highest mortality rate, the first being lung cancer.  An estimated 186,320 new 
cases and 28,660 deaths are expected in 2008, fortunately down from 232,090 estimated 
cases and 28,905 deaths in 2005 (7).  Being the leading cancer in the male population, the 
pathology of prostate carcinoma has become increasingly important, serving as potential 
targets for therapeutic agents.  The pathology has been hard to define due to a complexity 
of multiple integrating pathways that could potentially lead to the progression of prostate 
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tumors, although gene mutations, amplifications, deletions, and chromosomal 
rearrangements seem to be the basis for carcinoma.  It is uncertain if the androgen 
receptor serves a concrete role in prostate carcinoma development, but its quantification 
has shown an up regulation in the nucleus in BPH, PIN, and prostate cancer compared to 
normal prostate tissue levels.  There is an increasing heterogeneous localization of 
androgen receptor in the nucleus and cytoplasm in prostate cancer (1).  Most first line 
prostate cancer therapeutic agents are androgen suppressors that deplete androgen-
dependent cells through apoptosis, but inevitably select for and promote the emergence of 
androgen-independent prostate cancer cells (8).  Some of these androgen-independent 
cancer cell lines, PC3 and DU145, have continuous high androgen receptor expression 
for androgen receptor mediated cell growth (1).   
There are many characterized mutations of tumor suppressor and oncogenic proteins 
that affect the metastatic nature of prostate cancer, such as an over-expression of the Ras 
family and Myc oncogenes or mutations in tumor suppressors, such as PTEN, p53, and 
Rb that lead to increased proliferation and decreased apoptosis.  Prostate cancer is also 
hallmarked by mutations resulting in the loss of specific adhesion factors or keratin 
patterns.  One of the most notable losses is E-cadherin, which allows for cell-to-cell 
adhesion.  Its loss is found in over 50% of prostate tumors, pointing to its importance in 
tumor progression.  In addition to losses, a normal prostate epithelial cell may undergo 
stressors, such as phagocytic inflammatory cell damage, oxidative stress, or DNA 
damage, which expands the intermediate epithelial cell line and leads to the proliferative 
inflammatory atrophic (PIA) cell.  Further accumulations of somatic gene alterations 
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push the atrophic cells into PIN, and with even more accumulations of genomic changes 
(gain of oncogenes or loss of tumor suppressors) the original altered cells become an 
invasive carcinoma (1).  Therefore, proliferative inflammatory atrophic sites within the 
prostate are believed to serve as a jumping stone into proliferative atrophy neoplasm and 
prostate cancer and reflect focal lesions that are associated with chronic prostatic 
inflammation (8).   These atrophic areas are characterized by proliferative atrophic 
appearing epithelial cells that fail to differentiate into luminal secretory cells and are 
localized to the periphery of the prostate near inflammatory cells, where most cancers are 
suspected to arise (1, 8).  
There are multiple and highly accessible screening tools for this disease.  Digital 
rectal exams (DRE) are manually performed by a licensed medical professional who 
palpates the prostate per rectum.  The DRE allows for the diagnoses of BPH and early-
stage prostate cancer that is still localized to the primary site.  A second screen tool is the 
PSA test, which is an organ specific test that quantifies the amount of PSA leaked into 
stromal cells that then enters the blood stream and is metabolized in the liver.  A third 
tool is the Gleason grade, which serves as a marker to measure the extent of malignant 
prostatic tissue.  The Gleason system is based solely on the architectural pattern of cells 
within the prostate gland, with scores ranging from 1 to 10.  Gleason scores of 1 and 2 
represent a tumor consisting of closely packed uniform, single, and separate glands, 
representing well differentiated cells.  Gleason score of 2 through 4 also represent well 
differentiated cells; Gleason score of 5 to 6 represent moderately differentiated cells; 
Gleason score 7 are moderately poorly differentiated cells; and Gleason score of 8 
7 
through 10 is poorly differentiated cells (characteristic of invasive and aggressive tumors) 
(1).  
 
Prostate Epidemiology  
As previously noted, prostate cancer is the leading cancer diagnosed in males with the 
second highest mortality rate (7).  Genetics, diet, lifestyle, age, and familial history of 
prostate cancer all can potentially contribute to the development and progression of 
prostate malignancy (1, 8).  Age is one of the most important indicators for prostate 
cancer.  The distribution of incidence cases ranges from 35 through 85+ years of age, 
with 86.1% of those cases seen between ages 55 and 84 and 68 years old being the most 
common age of diagnosis.  The highest percentage of deaths due to prostate cancer is 
after the age of 75, with a median age of 80.  Males have a 15.78% (1 in 6) lifetime risk 
of being diagnosed with prostate cancer and a 2.83% lifetime risk of dying from prostate 
cancer; black males have an 18.25% lifetime diagnosis and 4.43% lifetime death risk, and 
white males a 15.25% and 2.65% risk.  It is shown that Asian men have low incidence 
rates, northern European countries having a higher incidence, but the highest always 
occurs in African American men (9).   
Some dietary risks have been contraindicated in prostate cancer (1, 8, 9).  An increase 
consumption of animal and saturated fats, red meat, dairy products, and calcium has been 
indicated in increasing the risk of prostate cancer (8), via increases in cell proliferation 
and angiogenesis and decreases in cell differentiation and apoptosis (1).   Vitamin E and 
selenium have been shown to decrease the risks (1, 8, 9).  It has been postulated that diets 
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in different geographical locations may contribute to the incidence variation between 
populations.  For example, in the 1980’s Asian males that consumed more soy products 
containing phytoestrogens had a 1 in 100,000 incidence rate of prostate cancer, whereas 
African American males had an incidence rate of 82 in 100,000.  Some lifestyle habits, 
such as tobacco smoking or alcohol consumption, have also been postulated to modulate 
prostate cancer risks, but have no definitive correlation (1, 9).   
It is proposed that acute and chronic alcohol consumption leads to the decrease of 
circulating testosterone, which in return is unable to act on the prostate in an androgen 
dependent manner, potentially altering the risk of prostate cancer.  However, inconclusive 
case studies have been reported.  Tobacco smoking does have a positive correlation to 
lung cancer, but has no direct correlation to prostate cancer development.  Although, it 
has been shown that tobacco smokers have a higher prostate cancer mortality risk, 
potentially due to the carcinogens in tobacco that promote tumorigenesis and gene 
mutation (1).  Other lifestyle habits or choices, such as men that have undergone 
vasectomies (9), certain occupations, and even non-steroidal anti-inflammatory drug 
consumption, have shown conflicting results in the modulation of prostate cancer (1).   
The most controllable prostate cancer risks reside with diet and lifestyle changes, but 
the uncontrollable sequential genetic alterations within the prostate can promote cancer 
progression.  Many somatic loss of heterogeneity changes occur in prostate tumor 
progression, especially the partial or total loss of chromosomes.  Such examples can be 
found on chromosome 8p, 10q, 16q, 19p, and 19q, with the loss of 19p and 19q 
chromosome arms seen more often in end-fatal prostate cancers.  Tumor progression by 
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loss of chromosome segments can be reversed by chromosomal transfer, in which some 
regions of transferred chromosomes suppress cell metastases, such as chromosome 8 and 
11 (1).  Many genes have been identified and hallmarked in organ-specific cancers, such 
as BRCA1 and 2 in breast cancer.  The identification of prostate-specific gene markers 
has been evaluated through genetic mutations and alterations in families with prostate 
cancer clusters (1, 9).  It is believed that 5% to 10% of prostate cancer is primarily due to 
inherited susceptibility genes (8) or more specifically hereditary prostate cancer genes 
(1).  Family and twin studies have concluded the risk of a male being diagnosed with 
prostate cancer increases if a brother or father had prostate cancer, producing a two to 
three-fold increase in the risk (9).  Other studies have resulted in a link between breast 
cancer and prostate cancer, showing an increase in prostate cancer risk in men with a 
family history of breast cancer in his mother and/or sister(s) (1, 9).  
 
Prostate Cancer Cell Lines 
Determining the parameters that control the metastatic nature of prostate cancer and 
the events during cancer progression define the importance of developing and 
investigating cancer cell lines.  In order to investigate the variances between non-
metastatic and metastatic tumor cells, the most recognized prostate cancer cell lines have 
been used, PC-3, DU-145, and LNCaP (10).  Although these three prostate tumor cell 
lines are widely used, they share no genetic background and were all derived from 
metastatic sites, not the primary prostate tumor, raising concern to their aneuploid 
karotype.  The development of a genetically related prostate carcinoma cell line came 
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about through the immortalization of prostate epithelial cells, P69, directly from the 
prostate gland.  Through in vivo injections into athymic nude mice the formation of a 
metastatic cell line, M12, arose.  The P69 parental prostate cell line and its sublines 
provide an opportunity to study the genetic variances between metastatic-tumorigenic 
cells versus non-metastatic and barely tumorigenic cells and what potentially allows for 
the emergence of metastatic phenotype during human prostate epithelial tumor 
development (11). 
The DU-145 cell line was obtained in 1975 from a 69-year-old Caucasian male with 
primary prostate carcinoma and multiple metastatic sites.  The sample was collected from 
one of the prostatic metastatic sites, a central nervous system lesion.  These cells, which 
possess K8 and K18, are tumorigenic in nude mice, have anchorage-independent growth, 
and lack PSA.  In addition, these cells are not responsive to hormones, nor are they 
dependent.  DU-145 produce high levels of EGF and TGR-α along with high levels of the 
EGF-receptor, all of which act in an autocrine fashion to stimulate cell proliferation.  
These cells also produce insulin-like growth factor-1 (IGF-1) and IGF-receptors, which 
can be exogenously stimulated by IGF.  TGF-β causes cell proliferation inhibition.  An 
up regulation of transferrin receptor has been noted.  The up regulation and possible 
amplification of some growth factor and growth factor receptors is believed to cause the 
androgen de-sensitivity (10). 
The PC-3 cell line is a poorly differentiated prostatic adenocarcinoma obtained from 
the lumbar vertebra metastatic site of a 62-year-old Caucasian male with primary prostate 
carcinoma.  These cells possess K8 and K18, are believed to be absent of PSA, and are 
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hormone unresponsive, although faint staining of PSA and nuclear androgen receptor 
have been reported.  PC-3 cells express high levels of TGF-α and EGF-R mRNA, which 
may contribute to their autonomous growth or androgen independence.  Up regulation of 
transferrin receptor is also noted, with an increased growth of both PC-3 and DU-145 
cells in the presence of bone marrow transferrin.  PC-3 cells are inhibited by exogenous 
TGF-β with initial exposure, but return to normal and express high affinity for TGF-β 
receptors and secrete active TGF-β.  These cells are also anchorage growth independent 
(10).   
LNCaP cells were derived from the metastatic site of the lymph node in a 50-year-old 
Caucasian male diagnosed with moderately differentiated primary prostate carcinoma.  It 
is important to note that this patient was treated with estrogen and hormone therapies 
without much success.  These cells possess K8 and K18, like PC-3 and DU-145, and have 
a low anchorage growth dependency.  Unlike the PC-3 and DU-145 cells, LNCaP cells 
have PSA, PAP, nuclear androgen receptor, and are androgen responsive for cell 
proliferation control.  LNCaP cells secrete EGF and TGF-α, and through androgen 
binding to androgen receptors the EGF-R is up regulated, thus providing a growth model 
of hormone and growth factor co-stimulation.  TGF-β did not affect cell proliferation 
(10).  Chung et al. produced a human prostate cancer progression model from the LNCap 
cells, beginning with the subcutaneous injection of LNCap and osteogenic sarcoma cells 
into male athymic mice, later castrating them and harvesting the tumors, creating the first 
subline LNCap-C4.  Successive introduction of harvested tumors into nude mice created 
multiple sublines beginning with androgen responsive LNCap-C4 cells and progressing 
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to LNCap-C4-2 and LNCap-B4, which display increasing androgen independence, 
invasiveness, and growth (12). 
P69 cells were isolated from portions of a benign prostate gland from a 63-year-old 
black male and immortalized with a SV40 large-T antigen gene construct.  These cells 
represent non-neoplastic epithelial cells without tumorigenic behavior or morphology.  
After subcutaneous injection of P69 cells into 18 athymic nude mice, 2 mice 
spontaneously developed tumors after a latency period of six months.  Those two tumors 
were isolated and through a series of in vitro passages and three in vivo passages a highly 
metastatic and tumorigenic M12 subline was produced (10, 13).  The M12 subline 
produced tumors in all mice following intraprostate injection, showing extensive 
metastatic distribution through the lungs, diaphragm, and often into the bladder, but 
without obvious metastases to bone.  The tumorigenicity and metastatic nature of the 
M12 subline never declined through in vitro passages (15).   Both the P69 cell line and 
M12 subline also lack the androgen receptor and are androgen unresponsive (11).  The 
conversion of the parental cells into fully metastatic cells was accompanied by several 
chromosomal alterations, including an unbalanced translocation between chromosomes 
16 and 19, resulting in the loss of 19p and partial loss of 19q (14, 15).  The breakpoint on 
chromosome 16 is near a site most frequently deleted in human prostate adenocarcinomas 
that have lost 16q, which includes genes E-cadherin and c-myc (15).  The importance in 
the loss of chromosome 19 in the M12 metastatic cells was investigated with the 
restoration of a neomycin tagged human chromosome 19 via microcell-mediated 
chromosome transfer (MMCT), creating a hybrid subline, F6.  F6 is characterized by its 
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reduction in tumorigenicity in vivo through subcutaneous and intraprostatic injections 
into athymic nude mice and an increase in in vitro doubling time and anchor-dependent 
growth (14, 15) (Figure 1).  The F6 subline also shows a marked reduction in vimentin 
mRNA and protein levels compared to M12, correlating to a decrease in tumorigenic and 
metastatic behavior.  In addition, M12 cell line shows a positive expression of K8, the 
keratin found in basal cells (15). 
 
MicroRNA Biological Function 
Several layers of gene expression regulation occur within living organisms - 
transcriptional, post-transcriptional (mRNA processing, transportation, and stability), 
translational (protein production), and post-translational (protein stability).  MicroRNAs 
(miRNA) are small non-coding single stranded RNA molecules, only 21-22 nucleotides 
in length, that function as post-transcriptional mRNA regulators through the specific 
binding to complementary 3’ untranslated regions (UTR) of mRNA, causing a down 
regulation of a specific message through degradation or translation repression (16).  The 
targeted message(s) control multiple biological processes, including developmental 
timing, stem cell division, apoptosis, disease, and cancer (17).  In the early 1990’s, miR 
let-7 and lin-4 became the first discovered miRNA in the species Caenorhabditis elegans, 
(C.elegans) (18), which was found to be involved in normal larval development.  
Developmental disruptions occurred when these miRs were mutated (16).  A comparison 
of let-7 to the human genome found homologous sequences, suggesting miRNAs were 
not specific to lower eukaryotes.  miRNAs have been found in roundworm, plants, and  
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Figure 1.  Development of unique prostate cancer sublines from a non-neoplastic 
prostate epithelial cell, P69.  The P69 cell line was injected into 18 athymic nude mice, 
with two forming spontaneous metastases.  These metastatic tumors were retrieved, 
passed in vitro, and then passed three times in vivo in athymic mice, obtaining the 
metastatic and tumorigenic M12 cell line.  An unbalanced translocation between 
chromosome 16 and 19 was seen between P69 and M12, resulting in the loss of 
chromosome 19.  Reintroduction of chromosome 19 in the M12 cells produced the non-
metastatic and barely-tumorigenic F6 cell line.  
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animals (16).  As of October 2006, there were 474 known human sequences, with 
estimates of over a thousand unknown miRNA sequences, potentially constituting ~3% 
of the human genome.  An estimated 10,000 genes or 30% of the human genome are 
thought to be regulated by miRNAs (19).  Most miRNA have been found in intergenic 
regions and sometimes in clusters of several miRNAs.   A few other human miRNA 
genes are located within protein coding introns and occasionally exons (18), and also in 
exons and introns of noncoding mRNA (20).   
Several characterized miRNAs display essential functions during development, such 
as miR-273 involved in C. elegans nervous system patterning.  They can also function in 
multiple unrelated mechanisms, such as miR-14 in Drosophilia melanogaster stress-
response pathway and fat metabolism regulation.  In addition, many mammalian miRNAs 
have been characterized in development: miR-181 in the differentiation of mammalian 
haemopoietic cells towards B-cell development; miR-375 in mammalian pancreatic islet-
cell development and insulin secretion regulation; miR-143 during mammalian adipocyte 
differentiation; miR-196 in mammalian limb patterning; and miR-1 genes during 
mammalian heart development (21). 
 
MicroRNA Biogenesis 
Mammalian miRNAs go through multiple processing steps to yield the mature single 
stranded post-transcriptional regulatory RNA.  Processing starts with the synthesis and 
transcription of the primary-miRNA (pri-miRNA) from DNA using RNA polymerase II 
(16) (Figure 2).  A transcript is created ranging in size from several hundred nucleotides 
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Figure 2.  MicroRNA biogenesis overview.  The primary miRNA strand is transcribed 
by RNA polymerase II, which is then cleaved by a microprocessor complex composed of 
Drosha and DGCR8.  The cleaved product is a pre-miRNA hairpin loop structure 
containing the mature miRNA.  The pre-miRNA is transported out of the nucleus via 
Exportin-5 in a Ran-GTP manner, with release of the pre-miRNA in the cytoplasm upon 
hydrolosis of GTP to GDP.  Once in the cytoplasm, the pre-miRNA is recognized by 
Dicer, which cleaves it to release a double-stranded miRNA complex.  Dicer then 
unwinds the double-stranded complex, releasing and guiding the mature miRNA strand 
into the RISC complex (16).  
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to several kilobases (22) and has a capped 5’ and poly-adenylated 3’ end (17).  This pri-
miRNA contains the mature miRNA sequence within a distinct stem-loop structure 
(Figure 3).  Next, a heterodimer microprocessor complex, consisting of two copies of the 
double-stranded-RNA-binding protein DGCR8 and two copies of the RNase III 
ribonuclease Drosha, initiates the binding and cleavage of the double stranded pri-
miRNA (23).  DGCR8 functions by directing Drosha in the specific processing of pri-
miRNAs.  Drosha cleaves the pri-miRNA at the base of the stem-loop, introducing a 2-
nucleotide 3’- overhang and 5’ phosphate at the cleaved site, resulting in the excision of a 
~60 nucleotide precursor RNA strand, pre-miRNA (20).  The pre-miRNA is transported 
out of the nucleus into the cytoplasm in an exportin-mediated and Ran-GTPase manner 
(24, 25).  Exportin 5 is a karyopherin nucleocytoplasmic transport factor that requires 
Ran-GTP to bind the double stranded pre-miRNA and facilitate nuclear export (24).  
Exportin 5 is dependent on RNA structure, requiring at least 17-double stranded 
nucleotides, but independent of sequence. Upon export into the cytoplasm, hydrolysis of 
Ran-GTP to Ran-GDP induces the release of pre-miRNA from Exportin 5 (20).   
The free cytoplasmic pre-miRNA is recognized by Dicer, another RNase III 
ribonuclease, by high affinity for the 5’ phosphate and 2-nucleotide 3’ overhang (20) and 
binds to the base of the stem-loop.  Following binding, the ribonuclease symmetrically 
cleaves the double stranded pre-miRNA stem-loop approximately two helix turns from 
the first cleaved site, introducing the second 5’ phosphate and 2-nucleotide 3’ overhang 
(26).  This second cleavage process produces a ~22 nucleotide double stranded 
miRNA:miRNA* duplex that remains associated with Dicer and is unraveled by an  
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Figure 3.  The structure of the pri-, pre-, and mature miRNA are located within a 
distinct hairpin loop structure.  The pri-miRNA is a long RNA transcript that upon 
cleavage releases a shorter pre-miRNA with a 2 nucleotide 3’ overhang and a phosphate 
attached to the 5’ end.  Further cleavage of the pre-miRNA creates a double stranded 
complex with two ends that both have 2 nucleotide 3’ overhangs and a phosphate 
attached to the 5’ end (16). 
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unknown RNA helicase (20).  The mature miRNA, or guide strand, is one strand of the 
duplex that is asymmetrically incorporated into the RNA induced silencing complex 
(RISC) (17, 20).  This asymmetric incorporation is due to RISC’s choice of the strand 
whose 5’ end is less tightly paired (26) and is crucial for the stability and proper loading 
into the RISC complex (21).   The other strand, denoted miRNA*, gets degraded (18).  
The mature miRNA guides RISC to mRNAs with a partially complementary sequence to 
the miRNA (16). 
miRNAs function through the 5’-end of miRNA base-pairing with RNA targets (27, 
28), creating a  down regulation of gene expression by either of two posttranscriptional 
mechanisms: direct mRNA endonucleolytic cleavage or translational repression (17, 29).  
A perfect complementarity of the miRNA to mRNA results in the cleavage of the mRNA 
by RISC at nucleotide pairing position 10 and 11, with regard to miRNA target.  If there 
is less extensive complementarity between miRNA and RNA target, the mRNA will be 
translationally repressed, potentially by de-capping or de-adenylating, resulting in mRNA 
cleavage (29) (Figure 4).  The miRNA 5’-end has been found to be evolutionarily 
conserved, containing a “seed” region (nucleotides 2-8) that is thought to be responsible 
for the specificity of base-pairing to the 3’ UTR of the target mRNA (21, 29).  A 
mutation in one nucleotide between 2 and 8 will cause loss of miRNA function, whereas 
a mutation in either nucleotide 1, 9 or 10 does not alter expression.  The extensive base-
pairing of the 5’-end of miRNA marks an important target site function, with a noted 
importance in the nucleotide positions 2 through 8.  There are three proposed base-
pairing mechanisms that allow miRNA to bind target mRNA - canonical miRNA:mRNA  
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Figure 4.  MicroRNAs function by repression of target mRNA.  The RISC complex 
with the mature miRNA target mRNA through mRNA cleavage and degradation (top 
left) or mRNA translation repression (bottom right).  mRNA cleavage is achieved when 
the mature miRNA has perfect or near perfect binding to the 3’ UTR of the target mRNA.  
mRNA translation repression occurs when imperfect matching occurs between the mature 
miRNA and 3’ UTR of the target mRNA (16). 
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interaction where both the 5’- and 3’-end of miRNA is used in binding, seed 
miRNA:mRNA interaction that requires strong 5’-end of miRNA binding to mRNA and 
little to no 3’-end pairing, and finally, 3’-compensatory interaction that needs a strong 3’-
end of miRNA binding to mRNA and weak 5’-end pairing.  Although the 3’-end of 
miRNA tends to be conserved, there has not been any role ascribed to the 3’-end (29).   
 
MicroRNA Relation in Cancer 
In healthy cells, the level of miRNAs and their targets are well balanced.  A 
disturbance of miRNA expression by either over expression or knock-out may contribute 
to the initiation and maintenance of tumors (21, 30).  The development of cancer is 
dependent on interactions between oncogenes that promote cell proliferation and 
tumorigenesis and tumor suppressor genes that repress cell division and tumor formation.   
Cancer is described by five stages, initiation, promotion, malignant conversion (reduced 
cell death and enhanced cell division), progression, and metastasis.  A simplified view of 
cancer is the amplification or over expression of oncogenes and suppression or deletion 
of tumor suppressors (16). 
Initial evidence showed a potential role for miRNAs in cancer with the 
characterization of the 13q14 deletion in human chronic lymphocytic leukemia (CLL).  
13q14 deletion has been seen in over half of the patients diagnosed with B cell-CLL (B-
CLL).  It was observed that miR-15a and miR-16a were located within the deleted region 
in B-CLL patients and approximately 68% of CLL patients had absent or down regulated 
miR-15a and miR-16a levels.  miR-15a and miR-16a negatively regulates BCL2 (an 
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apoptotic protein), thus promoting cell proliferation (17).  Following the initial evidence 
in humans, many experimental mechanisms arose to evaluate the role of miRNAs in 
cancer through profiling of miRNAs in both cancerous and normal tissues (16).  Taqman 
PCR has been used to evaluate precursor or active miRNA levels in tissue samples.  The 
most widely used analysis is the oligonucleotide miRNA microarray analysis, which 
utilize high through-put analysis of known miRNAs in numerous malignant and normal 
tissue samples to create a profile showing the distinct pattern of over expressed and down 
regulated miRNA gene expression (31).  A microarray screen by Gaur et al. (2007) 
quantitated the level of 241 mature human miRNAs in 13 normal tissue samples and 59 
tumor cell lines, showing a significant reduction of miRNA expression in cancer cell 
lines (32).  In addition, other microarray screen data has shown the following differential 
tissue miRNA expressions: miR-221, miR-222, and miR-146 up regulated in thyroid 
tumors; miR-143 and miR-145 reduced in colorectal neoplasia; miR-125b, miR-145, 
miR-21, and miR-155 lower in breast cancer; miR-221 higher in gliobastoma multiforme 
brain cancer and miR-181 lower in expression; let-7 down regulated in lung cancer 
targeting Ras oncogenes; over expression of the miR-17-92 cluster in lung cancer 
targeting PTEN and RB2 tumor suppressors (17, 31); and finally up regulated BIC gene 
expression in Hodgkin and Burkitt lymphoma with the BIC gene encoding miR-155 (16). 
Currently, the main mechanism that underlies changes in miRNA function in cancer 
cells compared to corresponding normal tissues is aberrant gene expression, thus 
resulting in abnormal levels of mature and/or precursor miRNA.  The genetic 
abnormalities that influence the activity of miRNA’s in cancer are the same abnormalities 
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seen in protein-coding genes, such as chromosomal rearrangements, genomic 
amplifications or deletions and mutations (31), providing further evidence of a role for 
miRNAs in cancer pathogenesis (32).  The proposed causes of abnormal miRNA 
expression have been the location of miRNAs at cancer-associated genomic regions 
(CAGRs), epigenetic regulation of miRNA expression, and abnormalities in miRNA-
processing genes and proteins (31, 33).   
miRNAs are shown to be found in genomic regions that are prone to alteration in 
cancer cells, including regions of loss of heterozygosity (LOH) near tumor-suppressor 
genes and regions of amplications containing oncogenes (31).  Fifty percent of annotated 
human miRNAs are located in fragile break sites near putative tumor suppressors and/or 
oncogenes associated in cancer (21).  In addition, many miRNAs are found within 
clusters on particular loci that have a high frequency of genomic alteration in human 
cancers.  For example, deletion of the locus containing miR-15a and miR-16-1 genes will 
no longer allow for the repression of BCL2 resulting in a decrease in apoptosis (31).  
Epigenetic changes, defined as mitotically and/or meiotically heritable changes in gene 
expression that are not accompanied by changes in DNA sequence (30), are hallmarked 
by DNA hypomethylation, CpG island hypermethylation, and histone-modification in 
malignant transformations.  For example, breast cancer cells with histone deacetylase 
inhibition and histone deacetylase inhibitor PBA showed significant alterations in levels 
of miRNA expression.  Another potential cause for disruption in miRNA expression is an 
alteration to any of machinery used during the biogenesis of miRNA, theoretically 
causing dramatic effects in expression.  The two most notable abnormal processes that 
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have been noted occur in either Drosha or Dicer processing.  Failure for Drosha to 
process pre-miRNA from pri-miRNA results in the reduction of mature miRNA.   As in a 
fraction of lung cancers, a reduced level of Dicer can alter miRNA levels and has shown 
correlation with a poor prognosis (31).  In addition, an increase in Dicer has been seen in 
prostate carcinoma along with a fourfold increase in expression of Dicer mRNA in the 
Burkitt’s lymphoma derived cell line (34). 
Despite the previous breakthroughs a role for miRNAs in cancer is still poorly 
understood, but suggests miRNAs could be potential targets for therapeutics.  Two 
proposed therapeutic approaches are available, blocking oncomiRs or restorive tumor 
suppressor-miRs.   Anti-miRNA oligonucleotides (AMOs) can potentially suppress onco-
miRNA activity, if the AMOs bind strongly to the miRNA and are physiologically stable.  
The same idea holds true for the opposite approach, but involves the introduction of 
modified oligonucleotides into cells that contain an under-expressed tumor suppressor-
miRNA (16). 
 
MicroRNA Role in Prostate Carcinoma 
One miRNA array screen performed by Porkka et al., analyzed 319 miRNAs in 6 
prostate cancer cell lines (i.e. PC3, DU-145, and LnCap), 9 prostate cancer xenografts 
samples, 4 BPH samples, 5 untreated prostate carcinomas, and 4 hormone-refractory 
prostate carcinoma clinical samples revealing 51 differentially expressed miRNAs when 
compared to BPH samples.  Of those 51 deregulated miRNAs, 27 were down regulated 
and 14 up regulated, suggesting global down regulation in cancer cells due to de-
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differentiation as seen in tumor cells compared to normal cells.  All down regulated 
miRNAs were found in hormone-refractory (androgen-independent), late-stage prostate 
carcinomas, with a smaller portion down regulated in untreated early carcinomas.  
Likewise, all up regulated miRNAs were found in hormone-refractory late-stage prostate 
carcninomas with fewer up regulated in untreated early carcinomas.  A few of these 
differentially expressed miRNAs include the downregulated let-7 family miRNAs, miR-
16/miR-143, and miR-145, which target the Ras oncogene, BCL2, and oncogenes 
ERBB2 and ERBB3, respectively.  In addition to the 14 up regulated miRNAs, 8 of them 
were shown to have increased expression in all carcinomas (miR-202, miR-210, miR-
296, miR-320, miR-370, miR-373, miR-498, and miR-503).  Porkka et al. showed a 
majority of down regulated miRNAs in prostate carcinoma, whereas a separate miRNA 
array screen performed by Volinia et al. profiled 540 tissue samples from six solid 
tumors, showed more up regulated miRNAs, 39, than down regulated, 6, in prostate 
cancer compared to normal tissue.  miR-21, miR-17-5p, miR-191, miR-29b-2, miR-223, 
miR-199a-1, miR-146, miR-181b-1, miR-20a, miR-32, miR-92-2, miR-214, miR-30c, 
miR-25, and miR-106a were shared with other solid cancers (35).  The vast difference in 
down or up regulated cancer between the two microarray screens shows the variability 
between sample numbers, technical platforms, and potentially the different analytical 
approaches (35).  As previously noted, some miRNAs are differentially expressed in 
other cancers, implicating that some cancers can share individual miRNAs, which could 
be used as prognostic markers in prostate cancer.  Explanations for the down regulation 
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or aberrant miRNA expression points to potential defects in miRNA biogenesis 
machinery or genomic alterations in cancer, as previously noted (36). 
Prostate cancer has been marked by a 2.5-fold up regulation of Dicer and significant 
increases of Exportin 5 in metastatic prostate cancer.  In normal prostate tissue, Dicer 
activity was limited to the cytoplasm of basal cells and negative in luminal cells.  PIN 
and prostate cancer showed Dicer in both basal and luminal cytoplasm, with PIN showing 
a two fold increase in Dicer over the normal prostate.  Dicer also increased with the 
pathological stage of prostate cancer, with the higher levels of Dicer seen in prostate 
cancer with a Gleason score greater than seven.  The level of Dicer in the neoplastic 
epithelial cells DU-145, LnCap, and PC-3 was compared against a non-tumorigenic cell 
line, RWPE-1, with the three metastatic cell lines showing higher Dicer levels within the 
cytoplasm.  Although it is seen that normal prostate tissue and organ-confined prostate 
cancer have relatively unchanged levels of Dicer, this is because normal prostate 
epithelial cells express Dicer only in basal cells, whereas organ-confined prostate cancer 
cells that express invasive properties no longer contain basal cells and all Dicer is found 
within luminal cells, citing a biological significance rather than quantitative.  In addition, 
as prostate cancer progresses and increases in metastatic nature the Dicer level increases, 
in correlation with the high Gleason score (34).  
 
MicroRNA-155  
Human miR-155 is encoded within exon 3 of the noncoding RNA BIC, a proto-
oncogene on chromosome 21 (37).  The BIC locus has been identified as a common 
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retroviral integration site in avian leukosis virus-induced B cell lymphomas and shown to 
promote malignant transformations upon deregulation.  In addition, the BIC locus is 
frequently associated with c-myc activation and preferentially found in metastatic tumors.  
The expression of BIC and miR-155 is the greatest in the lymphoid tissues, including 
activated B cells, T cells, macrophages and dendritic cells (38, 39), but can be seen 
widespread throughout other tissues and hematopoietic tissues (40).  The activation of the 
BIC gene and up-regulation of c-myc has been implicated in the pathogenesis and 
acceleration of lymphomas and leukemias.  An elevated relative BIC RNA level and 
miR-155 accumulation is seen in Hodgkin and children’s Burkitt lymphoma (41).  
Transgenic mice over expressing the mouse analog of miR-155 develop high-grade B cell 
neoplasms and exhibit splenomegaly and lymphopenia, suggesting the oncogenic 
properties of miR-155 during dysregulation (37).  In addition to the characterization of 
miR-155 in immune pathologies, it has been found over expressed in lung and colon 
cancer (35, 37), up regulated in pancreatic cancer progression (42), and three-fold higher 
in squamous cell carcinoma of the tongue compared to normal tissue (43).  Differential 
expression of miR-155 in breast cancer has shown both up regulated (35) and down 
regulated levels (16, 17, 33). 
miR-155 has  many target genes, including those involved in T cell co-stimulation, 
chemotaxis (ccl-5), signaling (IKBKE), and transcriptional regulation of c-Maf (38), 
BACH1 and Fos (39) (Figure 5A-C), along with many others.  One studied putative 
target of miR-155 is the large transcription factor c-Maf (38), belonging to the Maf 
family proteins (44).  Maf proteins activate transcription of target genes through the  
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Figure 5.  Putative miR-155 3’UTR targets.  (A) Two sites in BACH1’s 3’UTR that 
miR-155 targets. (B) One site in c-Fos 3’UTR that miR-155 targets. (C) Three sites in c-
maf 3’UTR that miR-155 targets. Lines represent base pairing, dots represent wobble 
base pairing. 
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binding to the Maf responsive element on target DNA.  Putative Maf targets are primarily 
involved in differentiation, but recent investigation detected potential targets involved in 
oncogenesis, such as c-Maf targeting the transcriptional induction of the tumor 
suppressor p53 (44). 
A more well known and studied target of miR-155 is the BTB and CNC homology 1 
(BACH1) transcription factor (39), broadly expressed as a transcriptional repressor (37)  
mapping to chromosomal region 21q22.1 (45).  BACH’s role has been well studied with 
relation to the breast cancer susceptibility gene BRCA1.  In cells containing BRCA1, a 
mutant BACH1 displayed impaired helicase activity which resulted in replication stress 
and formation of DNA breaks, contributing to chromatin instability.  In addition, cells 
having mutant BACH1 showed increase sensitivity to ionizing radiation (46).  The role of 
BACH1 as a DNA repair protein was further supported in the study performed by Peng et 
al., who confirmed the tumor suppressor abilities of BACH1 by noting the ability of cells 
to go through DNA repair in the presence of high levels of BACH1.  It was also 
concluded that a decrease in BACH1 led to increased DNA damage and cellular 
sensitivity to this damage, along with a delay in double-stranded DNA break repair (47).  
BACH1’s potential regulation by miR-155 was studied by Cullen et al. and Renne et al. 
through reporter systems using sensor constructs containing miR-155, 3’UTR targets 
fused to the reporter gene luciferase.  Both groups showed an inhibition of BACH1 
luciferase expression in a dose dependent manner when treated with miR-155 (37) (39).  
In addition, Renne et al. showed a decrease in BACH1 protein level via western blot in 
B-cell lymphoma cell lines expressing high levels of miR-155 (37).   
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MicroRNA-146a 
The human genome contains two miR-146 genes, miR-146a on chromosome 5 and 
miR-146b on chromosome 10, differing by only two nucleotides in the 3’ region of the 
mature form.  miR-146a expression has been widely studied in the immune system (48).  
Upon LPS stimulation, a rapid induction of miR-146 level is seen in human acute 
monocytic leukemia cells through Toll-like receptor 4 and a weak induction is seen in the 
presence of the pro-inflammatory cytokines IL-1 receptor-associated kinase 1 (IRAK1) 
and TNF receptor-associated factor 6 (TRAF6).  The involvement of these two pro-
inflammatory cytokines has been well established in toll-like-receptor and pro-
inflammatory signaling.  In addition, both IRAK1 and TRAF6 showed substantial drops 
in activity in the presence of miR-146a when evaluated by reporter systems, thus they are 
targets of miR-146a (19) (Figure 6).  This rapid production of miR-146 coupled with a 
decreased repression of signaling proposes a role for miR-146 to serve as part of a 
negative feedback loop, which negates the over activation of the innate immune system 
(19).  miR-146 has also been found to be up regulated in the rheumatoid arthritis synovial 
tissue (44, 49), papillary thyroid cancers (16, 17), CLL (33), and down regulated in germ 
cell cancers (33). 
 
Lin et al. reported a potential tumor suppressor role of miR-146a in androgen 
independent prostatic cancer.   A high expression of miR-146a was seen in androgen-
dependent LnCap and PC3-AR9 cell lines and in noncancerous prostatic epithelium, 
along with a progressive decrease in miR-146a during cancer progression.  The over 
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Figure 6.  Putative miR-146a 3’UTR target.  TRAF6 3’UTR.  Lines represents base 
pairing, dots represent wobble base pairing. 
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expression of miR-146 in androgen-independent PC-3 cell line resulted in a marked 
reduction in cell proliferation, invasion, and metastases.  It was shown that miR-146a 
targets ROCK1 protein kinase, which inhibits the transformation of androgen-dependent 
cells to androgen-independent, proposing a potential tumor suppressor property of miR-
146 (15). 
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PROJECT OBJECTIVES 
 
 Prior to the start of this project, a microarray screen was conducted comparing the 
expression of microRNAs between the F6 and M12 cell lines grown in vitro (2D) or 
embedded in extracellular matrix (3D).  microRNAs that showed significant fold 
differences between the two cell lines were determined to be potential tumor suppressor 
microRNAs or onco-microRNAs (oncomir).  Two differentially expressed microRNAs, 
which had higher expression in both M12 2D and 3D samples compared to F6, were 
miR-155 and miR-146a, suggesting possible roles as oncomirs..   
 The purpose of this project was to evaluate the role and biological activity of the 
two putative oncomirs, miR-155 and miR-146a, in a prostate cancer progression model.  
The initial steps were to confirm the preliminary microarray screening data and 
accurately quantitate the levels of endogenous miR-155 and miR-146a in the prostate 
cancer cell lines P69, M12, and F6 using quantitative real-time PCR analysis.  Secondly, 
miR levels were restored in the F6 cell line to M12 levels and the resulting effect on 
proliferation, motility, invasiveness, and putative target protein levels was evaluated.  
Lastly, the 3-dimensional morphological appearance of these stably altered cells was 
compared to the parental F6 and M12 cell lines. The overall objective of these studies 
was to determine if miR-155 and miR-146a qualify as oncomiRs, which warrant further 
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testing on metastatic tumor growth and metastatic behavior via injection in athymic male 
mice.
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MATERIALS AND METHODS 
 
2D Cell Culture 
Prostate cancer cell lines, P69, M12, and F6, were obtained in frozen aliquots at 
known passage numbers from Dr. Joy Ware (Virginia Commonwealth University, 
Department of Pathology, Richmond, VA).  Frozen cell aliquots were thawed in a water 
bath, resuspended in 10ml of media, centrifuged at 1700RPM for ten minutes to remove 
DMSO, supernatant aspirated, cell pellet resuspended with fresh media and directly 
plated on to 100mm x 20mm plastic tissue culture dishes (Falcon, 353003).  Cells were 
cultured in RPMI 1640 medium (GIBCO Invitrogen, 21870), supplemented with 5% FBS 
(Invitrogen, S11150), 1% L-glutamine (Invitrogen, 25030), 0.1% ITS (insulin, 5µg/ml; 
transferrin, 5µg/ml; and selenium, 5ng/ml), and 0.1% gentamicin 10mg/ml (Gibco, 
15710).  F6 cell media contained an additional 0.8ml of 50mg/ml geneticin (Gibco, 
10131) per 200ml of media to keep selective pressure for maintenance of chromosome 
19.  Cultures were incubated at 37
o
C in the presence of 5% CO2.  Media was replaced 
every 48 hours and cultures passaged at 80-90% confluency. 
 
3D Cell Culture 
Stably transfected F6 cell lines were cultured embedded within a basement 
membrane extract of extracellular matrix, referred to as Matrigel (R&D Systems, 3433-
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005-01).  Matrigel is a basement membrane extract purified from Englebreth-Holm-
Swarm tumor and is primarily composed of lamin, collagen IV, entactin, and heparin 
sulfate proteoglycan.  This compilation of extracellular proteins supports cell growth and 
is essential for tissue organization, cell adhesion, migration, proliferation, and 
differentiation.  It also provides major barriers to invasion by metastatic tumor cells.  
Matrigel was thawed on ice over night at 4
o
C and stored on ice at all times.  One well of a 
24-well plate was pre-coated with 20 µl of thawed Matrigel and placed in a 37
o
C 
incubator to promote polymerization.  2D cell cultures were rinsed with PBS (phosphate-
buffered saline, GIBCO Invitrogen), removed from the dish with trypsin-EDTA 0.25% 
(GIBCO Invitrogen, lot # 39808), resuspended in serum media, centrifuged at 1700 RPM 
for ten minutes, supernatant aspirated, and cells counted using a hemacytometer. One 
million cells were carefully resuspended in 500µl of Matrigel on ice, transferred onto the 
pre-coated well, and then placed in the incubator for 15 to 30 minutes to allow 
polymerization of the matrigel-cell suspension.  Finally, 250µl of media containing 5% 
Matrigel was applied on top of the cell suspension and incubated for up to 12 days.  The 
top layer of media was replaced every two to three days with 250µl of fresh serum media 
with appropriate antibiotic selection. 
 
Cell Counting 
Cells were rinsed with PBS and removed from culture dishes by trypsin-EDTA 
digest.  The trypsin-cell suspension was neutralized with fresh media containing FBS and 
centrifuged at 1700RPM for 10 minutes.  Cell pellets were resuspended in 1mL of media.  
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Resuspended cells (100µl) were treated with 900µl of Tryptan-blue solution and loaded 
on to a hemacytometer.  The average live-cell count was used to estimate the total 
number of cells present and the amount of cell-containing media needed to ensure the 
correct experimental number of cells needed for transient and stable transfection, 3D-
Matrigel growth, and cell proliferation assays. 
 
Oligonucleotide Design 
The mature DNA sequence of human miR-155 and the precursor DNA sequence 
of human miR-146a was identified using online software (http://microrna.sanger.ac.uk/, 
2008) and appropriate oligonucleotides designed (see, bold Table 1.).  miR-155 
oligonucleotides were manufactured by Invitrogen, using Hind III and Bgl II compatible 
ends for ligation into the pH1-RNApuro (ph1pa) plasmid vector (Figure 7).  The miR-
146a oligonucleotides were manufactured by Integrated DNA technologies, containing a 
5’- BamH I restriction site overhang on the top strand, and 5’- EcoR I restriction site 
overhang on the bottom strand (see bold, Table 1), which allowed for directional cloning 
of the annealed oligonucleotides into the pSiren-RetroQ vector (Clontech, 631526) 
(Figure 8).  In addition, the designed oligonucleotides contained the recommended 7-9 
nucleotide hairpin loop sequence, 5’-TTCAAGAGA-3’, as outlined in the Clontech 
protocol (PT3739-1).  The Xba I restriction site (5’-TCTAGA-3’) was also incorporated 
on both top and bottom strand to create a novel restriction site for confirmation of 
plasmid insert.  Correct cloning of DNA insert was confirmed through sequencing. 
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Table 1.  Designed oligonucleotides of mature miR-155 and precursor miR-146a. 
 
 
miR-155 Sense 5’-GATCCCCTTAATGCTAATCGTGATAGGGGTTTT-3’ 
miR-155 Antisense 5’-AGCTAAAACCCCTATCACGATTAGCATTAAGGG-3’5’ 
miR-146a Sense 5’GATCCGTGAGAACTGAATTCCATGGGTTTTCAAGAGA
AACCCATGGAATTCAGTTCTCATTCTTTTTTTCTAGAG-3’ 
miR-146a 
Antisense 
5’AATTCTCTAGAAAAAAAGAATGAGAACTGAATTCCAT
GGGTTTCTCTTGAAAACCCATGGAATTCAGTTCTCACG-
3’ 
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Figure 7.  pH1-RNApuro vector. 
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Figure 8.  pSiren-RetroQ vector.  
41 
Oligonucleotide Ligation 
Each designed oligonucleotide pair, miR-155 forward and reverse and miR-146a 
forward and reverse, were spun down at 8,000RPM for five minutes and then diluted with 
1X Tris-EDTA (1X TE) Buffer pH 7.5 to achieve a final concentration of 100 µM.  Five 
microliters of each oligonucleotide pair were mixed together (10µl total volume, 50µM 
concentration) and annealed by the  following thermal conditioning: 95
o
C for 2 minutes, 
72
o
C for 2 minutes, 37
o
C for two minutes, 25
o
C for two minutes.  Samples were then 
stored at -20
o
C for further DNA ligation experimentation. 
 
Restriction Endonuclease Digestion 
Restriction endonuclease digestions were performed on both pH1-RNApuro and 
pSiren-RetroQ plasmid vectors.  10uL (200ng) of pSiren-RetroQ plasmid vector 
(Clontech, 631526) was digested for 12 hours in a 37
o
C water bath with 2µl 10X NE-
EcoR I buffer (New England Biolabs, Ipswich, MA), 4µl of H2O, 2µl 10 X BSA, and 1µl 
of both BamH I and EcoR I (New England Biolabs).  After digestion, the mixture was 
placed on heat block at 80
o
C for 20 minutes to inactivate restriction enzymes.  The pH1-
RNApuro vector was digested under the same conditions with 10uL of the vector, 2µl 
10X NEbuffer 2 (New England Biolabs), 2µl 10 X BSA, 1µl of both Hind III and Bgl II 
(New England Biolabs, Ipswich, MA), and 4µl of H2O. 
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DNA ligation 
In a sterile microcentrifuge tube the double stranded oligonucleotides were diluted 
to a 0.5µM concentration.  All reagents are from New England Biolabs, Ipswich, MA, 
unless otherwise noted.  Ligation was carried out for both microRNA-vector pairs by 
combining 2µL of digested linearized vector (25ng/µl), 1µl of diluted annealed double 
stranded oligonucleotide (0.5µM), 1.5µl 10X T4 DNA Ligase Buffer, 0.5µl BSA 
(10mg/mL), 0.5µl T4 DNA ligase (400U/µl), and 9.5µl nuclease free water.  A control 
ligation for each was also carried out, replacing the 1µl of diluted annealed 
oligonucleotide with 1µl of nuclease free water.  All ligation mixtures were incubated at 
room temperature for three hours, then immediately put on ice or stored at -20
o
C.   
 
Bacterial E. Coli Transformation  
One hundred microliters of competent E. Coli bacterial cells stored at -80
o
C were 
thawed on ice for ten minutes.  Five microliters of ligation product (pSiren-Retroq+miR-
146a, pSiren control, pH1-RNApuro+miR-155, and pH1-RNApuro control vectors) were 
added to individual thawed cell aliquots and incubated on ice for 15 minutes.  Following 
incubation, cells were heat shocked in a water bath at 42
o
C for 15 seconds, then returned 
to ice for two minutes.  The transformation reaction was diluted with 250µl of Luria-
Bertani (LB) media and incubated at 37
o
C for 60 minutes while being shaken at 
250RPM.  Two-hundred microliters of the mixture was plated on LB agar plates 
containing 10µg/ml ampicillin, set upright for 15 minutes, then placed upside-down and 
incubated for 12 hours at 37
o
C.   
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Small Scale DNA Preparation 
After E. Coli transformation, many single colonies from the freshly streaked 
experimental plates were selected to inoculate individual cultures of 5ml LB media 
supplemented with 5µl ampicillin and incubated at 37
o
C for 12 to 16 hours with shaking 
at 250RPM.  Following incubation, the expanded colonies were pelleted in a 
microcentrifuge tube by centrifugation at 13,000RPM at room temperature for three 
minutes.  After aspirating the supernatant from the cell pellets, the plasmid DNA was 
purified using QIAprep Miniprep Kit (QIAGEN, 27106) per manufacturer recommended 
protocol.  The purified DNA was stored at -20
o
C. 
 
Agarose Gel Electrophoresis 
 Each experimental vector clone was analyzed by digestion with appropriate 
restriction enzymes.  All reagents and restriction enzymes are from New England 
Biolabs, Ipswich, MA , unless otherwise noted.  Purified pSiren-RetroQ+miR14a DNA 
(1µg) from the small scale DNA preparation was combined with 9uL of nuclease free 
water, 2µL of NEBuffer 2, 2µL 10X BSA, 1 µL Xba I, 1µL Afl III, and incubated 
overnight in a 37
o
C water bath.  pH1-RNApuro+miR-155 purified DNA (1µg) was also 
digested overnight in combination with 7.5µL nuclease free water, 2µL NEBuffer 2, 2µL 
10X BSA, and 0.75µL of each Xho I, Nhe I, and Hind III.  A 1% agarose gel was 
prepared using 1.0g agarose in 100mL 1X Tris/Borate/EDTA (1X TBE), along with 2µL 
of ethidium bromide.  Each digested mixture (20µl) was placed into individual wells and 
electrophoresed at 100V. A 1-kilobase DNA ladder was included.  The gels were 
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evaluated underneath ultra-violet light.  The vector containing the correct size and 
number of bases was selected for DNA sequencing. 
  
Sequencing 
The specific clone selected from agarose gel analysis was sent for sequencing at 
MCV-VCU Nucleic Acids Research Facilities (NARF).  Positive sequencing of the 
pSiren-RetroQ+miR-146a and pH1-RNApuro+miR-155 vectors containing the 
appropriate insert DNA was confirmed. 
 
Plasmid Purification 
Plasmid DNA from the correctly sequenced pH1-RNApuro+miR-155 vector, 
along with pH1-RNApuro vector without insert, was used to transform competent  E. 
coli.  Five colonies from the freshly streaked plate were used to inoculate a large scale 
250ml LB liquid culture.  Following overnight incubation with shaking at 37
o
C, the 
plasmids were purified using the Marligen High Purity Maxiprep Kit and manufacturer 
protocol (Marligen Biosciences, 11452) to obtain approximately 750µg of purified DNA. 
Plasmid DNA for the correctly sequence pSiren-Retroq+miR-146a, along with 
pSiren-RetroQ-NTC vector, was purified by Qiagen miniprep protocol, as previously 
outlined, without need for a larger scale purification. 
The 3’-UTR luciferase reporter constructs PLSV40-Bach1, PLSV40-Fos, and c-
Maf wild type, provided by Dr. Cullen and Dr. Rodriguez, respectively, were received 
spotted on filter paper.  Each spot was partially excised using a sterile razor, placed with 
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40µl of 1 X TE Buffer into a microcentrifuge tube, and vortexed vigorously.  Five 
microliters of the solution was transformed in 100µl of competent E. Coli cells, followed 
by inoculation and plasmid purification via the Marligen high purity maxiprep isolation 
kit. 
 
Generation of Stably Transfected Cell Lines 
F6 cells were transfected with the appropriate vector constructs, using TransIT-
LT1 transfection reagent (Mirus, MIR 2300).  F6 cells were transfected at a confluency of 
60-70% by pH1-RNApuro or pSiren-RetroQ vector constructs in a 3:1 ratio of TransIT-
LT1 reagent (3µl): vector DNA (1µg), for 48 hours in serum media, as outlined by the 
Mirus protocol.  Transfected cells were selected by antibiotic resistance using 300ng/ml 
of puromycin for three days or until all F6 cells containing no transfected plasmid were 
completely killed by puromycin selection.  Frequent media changes were conducted to 
remove lysed cells. 
Following high dose antibiotic selection, the remaining transfected F6 cells were 
gently trypsinized with diluted 0.05% Trypsin-EDTA and placed in a succession of 6-
well plates, 60mm dishes, then 100mm plastic tissue culture dishes, creating a 
heterogeneous mixture of stably transfected cells.  These cells were continually subjected 
to a maintenance antibiotic dose of 100ng/ml of puromycin. 
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RNA Purification 
mRNA was isolated from p69, M12, F6, F6+pH1PA-155, F6+pH1PA, 
F6+pSiren-146a, and F6+pSiren-NTC cells.  Total RNA was isolated from frozen or 
fresh cell pellets consisting of 1-2x10
6 
cells using the mirVana
TM
 miRNA Isolation Kit 
(Ambion, 1560).  The protocol was followed precisely as outlined by mirVana
TM
.  The 
concentration of purified RNA was determined by dissolving 5µl of the isolated total 
RNA sample in 95µl of RNAse-free water.  The absorbance of the diluted sample was 
measured at 260nm (A260) in a Smart Spec 3000 spectrophotometer (Bio Rad).  To 
determine RNA concentration in microgram per milliliter, the ratio of A260/A280 was used 
to assess the RNA purity (1.8-2.1 ratio range for highly pure RNA).  The remaining RNA 
was stored at -80
o
C for future analysis. 
 
cDNA Synthesis, Real Time- PCR 
The reverse transcription reaction was conducted on P69, M12, F6, F6+pH1PA-
155, F6+pH1PA, F6+pSiren-146a, and F6+pSiren-NTC cell lines utilizing the total RNA 
previously described.  The RT-PCR reaction was conducted using the Taqman 
MicroRNA Reverse Transcription Kit (Applied Biosystems, 4366596) and RoboCycler 
thermal cycler (Stratagene Cloning Systems, 400860).  All reagents used in the RT-PCR 
reaction are from the Taqman kit, unless otherwise noted.  The total RNA previously 
isolated, was diluted using elution buffer to obtain a 0.1 µg/µl concentration.  Small 
eppendorf tubes (0.5ml) were used containing 200ng (2µl) of RNA from each respective 
cell line, 4.162µl of nuclease free water, 0.15µl of 100mM dNTPs, 1.5µl of 10x RT 
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Buffer, 3 µl of experimental 5X TaqMan MicroRNA RT Primer (TaqMan MicroRNA 
Assay, hsa-MiR-146a, 4373383; or hsa-MiR-155, 4373124), 3µl of control 5X TaqMan 
MicroRNA RT Primer (Applied Biosystems, RNU48, 4373383), 0.188µl of RNase 
Inhibitor, and 1µl of MultiScribe Reverse Transcriptase, for a total volume of 15µl.  Each 
tube was gently mixed, quickly spun down, and then subjected to 30 minutes at 16
o
C, 30 
minutes at 42
o
C, and 5 minutes at 85
o
C to inactivate reverse transcriptase.  An additional 
30µl of nuclease free water was added to the 15µl total, for a final 45µl total, and then 
stored at -20
o
C to -80
o
C for future PCR reactions. 
 
Qualitative RT-PCR (qRT-PCR)  
To evaluate the presence of the specific microRNAs (146a and 155) within the 
cDNA samples, 3µl of RT-PCR cDNA, 1µl of 20X Taqman MicroRNA Assay Primer 
(hsa-miR-146a, hsa-miR-155 or hsa-RNU48), 7µl of sterile deionized water, and 10µl of 
2X Taqman Universal PCR Master Mix was placed in triplicates in a 96-well plastic plate 
(Applied Biosystems, 4303327), for a total volume of 20µl per well.  Both experimental 
microRNA and control RNU48 primer pairs were run together in triplicates.  The 96-well 
plate was prepared on ice in unlit conditions, and then centrifuged at 1,000RPM for 5 
minutes.  The 20µl reactions were incubated in an Applied Biosystems 7300 Real-Time 
PCR machine for 2 minutes at 50
o
C, 10 minutes for 95
o
C, followed by 40 cycles of 
denaturation for 15 seconds at 95
o
C and annealing/extension reaction for 60 seconds at 
60
o
C.  Data collection was obtained at the first step of stage three, the 15 seconds of 
denaturation at 95
o
C.   
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The threshold cycle (Ct) is the PCR cycle at which fluorescence of the primer 
rises above a minimal threshold.   In order to confirm the presence of miR-155, miR-146, 
and RNU48 among the cell lines, analysis of the Ct was performed based on the 
comparison Ct method. The equation is,  
   Ct = 2
-∆Ct, sample - ∆Ct, reference
 
A lower Ct value indicates a larger amount of starting material, i.e. more target 
mRNA.  The relative quantification of the target gene was normalized to the internal 
control gene, RNU48, to allow for variations in RNA integrity, RT-PCR efficiency, and 
sample loading. 
 
DNA Transient Transfection and Luciferase Promoter Assays 
Luciferase promoter assays were conducted using the Dual-Luciferase Reporter 
Assay System (Promega, E1910) and TransIT-LT1 transfection reagent.  The reporter 
assay system utilizes the measurements of two individual reporter enzymes, the 
experimental firefly luciferase and the control renilla luciferase.  The internal control 
minimizes experiment variability, due to differences in cell viability or transfection 
efficiency. 
Approximately 3x10
5
 cells were plated in triplicates in 6-well plates and grown 
over night to a confluency of 75%.  The transfection was carried out per Mirus protocol- 
incubating cells with reporter plasmid (0.8µg) and renilla plasmid (0.2µg) for 48 hours.  
After incubation, each well was washed twice with PBS, cells trypsinized, collected in 
1.5mL eppendorf tubes, and pelleted.  The cells pellets were washed twice with PBS and 
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repelleted with complete aspiration of PBS wash.  Following the PBS wash, cells were 
lysed with 200µl 1xPassive lysis buffer (PLB) and incubated in liquid nitrogen for 5 
minutes followed by incubation in a 37
o
C water bath for 5 minutes.  As described by 
Promega protocol, the PLB and lysed cells were centrifuged and supernatant collected for 
luciferase analysis.  Firefly and renilla luciferase readings were recorded on a 
luminometer.  Twenty microliters of PLB lysate was injected into luminometer tube, 
followed by sequential injection of 100µl of LAR II and Stop&Glo reagent, with 
measurements after each injection.  The final luciferase reading for each experimental 
well was a ratio of firefly luciferase and the partnered renilla luciferase reading and 
calculated as, 
 
 
Cell Proliferation Assay 
The effect of stably transfected microRNA-155 and microRNA-146a on the 
growth of the F6 prostate cancer cell line was assessed using the WST-1 Cell 
Proliferation Reagent (Roche, 11644807001).  Prostate cancer cell derivatives (M12, F6, 
F6+pH1-RNApuro-155, F6+pH1-RNApuro, F6+pSiren-146a, and F6+pSiren-NTC) were 
plated in 96 well plates (BD Falcon) at a concentration of 1x10
3
 cells per well.  Each cell 
line was plated in eight well in a total volume of 100µl per well (1x10
3
 cells/100µl), 
leaving empty wells to serve as experimental blanks, and incubated at 37
o
C in CO2 5%.  
One plate was read every other day, beginning with the first day following the initial 
plating and set as day 0.  On assay days all media was carefully aspirated from all wells, 
50 
100µl of serum-free media was added to each well, and 10µl of WST-1 Cell Proliferation 
Reagent (10% of media amount) was added to all experimental cell and experimental 
blank wells, and then incubated at 37
o
C for two hours.  The absorbance of each well was 
measured using an Elisa 312e Microplate Bio-kinetics Reader (BIO-TEK Instruments) at 
450nm.  Media was carefully aspirated and replaced every two to three days in remaining 
plates.  The absorbance of each cell line was averaged and normalized to the blank of 
each assay day, using the following equation, 
 
 
Migration Assay 
Cells were detached using 2-3mL of cell stripper (Cellgro, 25-056-CI), washed in 
serum-free media, and pelleted.  The pellets were resuspended in serum-free media to a 
density of 1x10
5 
cells/ml.  A cell suspension (2.5x10
4
 cells in 250µl) was added to the 
upper chamber of an 8.0um pore size Transwell filter insert (Corning Inc., 3422) and 
750µl of supplemented media (10% FBS and 2ng/ml EGF) was placed in the lower 
chamber of each well.  Cells were incubated at 37
o
C for 48hr.  Following incubation, the 
media from both lower and upper chambers was aspirated.  Cells were fixed by the 
addition of 1ml of 0.1% glutaraldehyde in PBS to the bottom chamber for 20 minutes at 
room temperature and then aspirated.  The filter was stained with 0.1% crystal violet in 
PBS for 30 minutes at room temperature.  The stain was thoroughly rinsed with deionized 
H2O.  Each filter was cut with a sterile blade, placed on a glass microscope slide, and the 
non-migratory cells on the upper surface of the filter were gently scrapped off using a Q-
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tip.  The filter was then mounted a slide using Permount and cells on the underneath side 
of the filter were counting in five random fields per filter at 400x magnification. 
 
Invasion Assay 
The same protocol was followed as with the migration assay with one additional 
step.  A Matrigel-serum-free mixture was added on top of each Transwell filter insert in 
order to assay the invasive properties of cell lines.  Twenty-five microliters of a 1:10 
dilution of Matrigel in serum-free media was placed on top of the Transwell filter and 
allowed to incubate at 37
o
C for twenty minutes, sufficient time for adequate 
polymerization.  Cells were added on top of the polymerized Matrigel and all other steps 
in migration assay remained as previously discussed. 
 
3D Immunoflourescence 
Serum media on top of polymerized Matrigel-cell mixture was aspirated.  The 
Matrigel-cell mixture (40µl) was removed by a pipette tip and 10 µl was placed into each 
chamber of a 4-well chamber glass slide (Lab-Tek, 154526).  The slide was allowed to 
completely air dry and fixed using 500µl of a 1:1 mixture of methanol/acetone at -20
o
C 
for 10min.  The methanol/acetone was discarded and the slide left to air dry.  Once 
completely dry, the slide was stored at -80
o
C or used immediately for staining.   
Each well was rinsed three times with 500µl of PBS (pH 7.4) for five minutes 
with gentle shaking.  To increase cell permeability 500µl of 0.5% Triton is applied to 
each well for 30 minutes with shaking.  Triton was aspirated and the plate is washed with 
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1ml of PBS for 5 minutes.  IF buffer (130mM NaCl, 5mM Na2HPO4, 3.5mM NaH2PO4, 
7.7mM NaN3, 0.1% BSA, 0.2% Triton-X 100, 0.05% Tween-20) was prepared.  400µl of 
IF buffer + 10% goat serum was added to each well and shaken at room temperature for 
1h to provide a primary block.  The primary block was aspirated, then each well was 
incubated with 200µl/well of a secondary block antibody (IF buffer + 10% goat serum + 
20µg/ml goat anti-mouse F(ab’)2 fragment) for 30-40 minutes.  The primary antibodies, 
α-6 integrin (Chemicon, MAB1378), β-1 integrin (Chemicon, MAB1981Z), β-4 integrin 
(Chemicon, MAB2058), vimentin (Sigma, V6630), E-cadherin (BD BioSciences), and β-
catenin (Santa Cruz Biotech, H-102) were diluted 1:200, 1:200, 1:200, 1:200, 1:50, and 
1:100, respectively, in the secondary blocking solution and incubated over night (15-18h) 
at 4
o
C.  Following steps were carried out avoiding light exposure.  Each chamber was 
rinsed with IF buffer for 10 minutes three times with gentle rocking.  200µL of IF buffer 
+10% goat serum + secondary antibody was added to each well and incubated at 4
o
C for 
40-50 minutes.  Mouse secondary antibody had green fluorescent dye and rabbit had red 
fluorescent dye.  Each well was subsequently rinsed three times for 10 minutes each with 
IF buffer and gently rocked at room temperature.  One drop of DAPI nuclei stain was 
applied to each well, a glass cover slip added, and incubated over night at room 
temperature.  The cover slip was mounted with clear nail polish and either stored at -80
o
C 
or evaluated immediately under confocal microscope. 
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3D Cell Harvest 
A mixture of 10mL PBS with 1% 0.5M EDTA and 1% protease inhibitor was 
chilled on ice.  The top layer of media was aspirated and 5mL of the chilled PBS solution 
was added to the Matrigel-cell mixture and dislodged by gentle scraping with a sterile 
pipette tip.  The PBS/EDTA/matrigel-cell mixture was placed into a 50mL tube and 
incubated in an ice bath for 1.5 hours while rocking.  After incubation the mixture was 
centrifuged at 1,000 RPM for 10 minutes at 4
o
C followed by careful aspiration of the 
supernatant.  The remaining 5mL of the PBS/EDTA/protease inhibitor mixture was used 
to wash the pellet, followed by repeated centrifugation.  The pellet was flash frozen in 
liquid nitrogen and stored at -80
o
C or used immediately for RNA, DNA, or protein 
isolation. 
 
Whole Cell Protein Extract (WCE) 
Cell pellets were obtained and lysed in 4% SDS in 1X PBS with protease inhibitor 
(Sigma, St. Louis, MO), the amount varied based on cell pellet size.  The SDS-cell 
mixture underwent sonification until the pellet was completely dissolved and the solution 
no longer viscous.  Following sonification, an equal volume of 1xPBS was added to each 
tube reducing the SDS concentration to 2%.  Lysates were centrifuged at 12,000RPM for 
10 minutes at room temperature, supernatant carefully collected into fresh 
microcentrifuge tubes and protein concentration measured using BioRad Dc Protein 
Assay Kit (BioRad, Hercules, CA).  Five microliters of each protein extract was mixed 
with 100µl of Bio-Rad Dc Protein Assay Reagent A (BioRad, 500-0113) that contained 
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2µl of Bio-Rad Dc Protein Assay Reagent S (BioRad, 500-0115), followed by the 
addition of 800µl of Bio-Rad Dc Protein Assay Reagent B (BioRad, 500-0114).  The 
protein assay solution (800µl) was added to plastic spectrophotometer curvettes and read 
at 750nm against an established standard curve to obtain protein concentration.   Each 
protein extract (60µl) was placed into a fresh microcentrifugation tube, 20µl of a 4X SDS 
loading buffer was added, heated at 95
o
C for five minutes, then immediately put on ice 
and placed at -20
o
C. 
 
Western Blot 
WCE protein (60µg) from selected cell lines was analyzed on a 4-15% Tris-HCl 
polyacrylamide gel (BioRad, 161-1158), electophoresed at 100 volts in 1xSDS running 
buffer (Tris 3.03g, glycine 14.4g, SDS 1g) for one hour.  The gel was transferred onto 
nitrocellulose paper at 30 volts for twelve hours in the presence of 1x transfer buffer (Tris 
3.03g, glycine 14.4g) at 4
o
C.  The membrane was washed in 1X Tris buffered Saline (1X 
TBST)(25mM Tris-HCl pH 7.5, 0.137M NaCl, 2.7mM KCl) three times for 5 minutes 
with gentle rocking, followed by incubation in 5% non-fat milk for 1 hour at room 
temperature with rocking.  The membrane was again washed in 1xTBST three times for 
five minutes, followed by incubation in 5% non-fat milk with primary antibody BACH1 
(Zymed, 37-0900) in a 1:500 dilution for 12 hours at 4
o
C.  The membrane was washed in 
1xTBST as previously stated, followed by addition of the secondary antibody in 5% milk 
for one hour at room temperature.  The membrane was washed three more times in 
1xTBST.  The membrane was then rinsed with equal amounts (200µL) of 
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chemiluminescence oxidizing reagent and enhanced luminal reagent (Western 
Lightning™, NEL104 and NEL105), allowing excess reagent to drip off, placed onto a 
glass plate, and developed in the dark room at the desired exposure time.  The same 
membrane was used over by adding stripping solution (100mM glycine, 10mM β-
mercaptoethanol (375µL β-mercaptoethanol/500mL) three times for 30 minutes at room 
temperature, followed by 1X TBST washing. 
 
Statistics 
 Following data analysis the standard deviation was calculated using the following 
equation, n represents the sample size 
. 
Standard error was then calculated using the following equation, where n is the sample 
size, 
. 
Each qRT-PCR reaction was run in three to four sets of triplicates, the luciferase assay in 
a single set of triplicates, the migration and invasion assays in two sets of triplicates, and 
the cell proliferation assay in a single set of eight samples.  Graphical analysis depicts 
plus and minus standard error. 
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RESULTS 
 
Differential microRNA expression via microarray analysis 
 Microarray analysis evaluating microRNA (miR) expression in the metastatic 
M12 cell line versus its non-metastatic, barely tumorigenic variant, F6, in both 2D (in 
vitro) and 3D (grown in extracellular matrix), was performed by Drs. Xueping Zhang and 
Zendra Zehner using established protocols via Applied Biosystems Taqman MicroRNA 
Assay System (Virginia Commonwealth University, Richmond, VA). Unpublished data 
showed the differential expression of miRs considered either as tumor suppressors (high 
in F6 and low in M12) or oncomiRs (high in M12 and low in F6).  The Ct value 
represents the amplification cycle number at which the miR RNA level accumulates past 
a set threshold and further correlates to the absolute amount of specific mRNA present.  
A low Ct value represents a large abundance of mRNA; a higher Ct value represents a 
lower abundance. Applied Biosystem’s software indicates that a Ct value ≤ 32 is 
considered valid.  Each Ct value was normalized to an internal control gene, RNU48.  
The expression fold difference of the normalized Ct values between cell lines was 
determined (RQ value).  miR-155 showed a 2.0-fold higher expression level in M12s 
grown in 2D and a 3.6-fold higher expression in M12 grown in 3D compared to F6. miR-
146a showed a 272.6-fold higher expression in M12 grown in 2D and a 3351.8 fold-
57 
higher difference in the M12 grown in 3D samples, compared to F6 (Table 2).  Thus, 
miR-155 and miR-146a show expression patterns typical of potential oncomiRs.  miR-
146a had some Ct values above the recommended Ct cut off, therefore these normalized 
RQ values are potentially over-inflated and require further validation.  
 
miR-155 has a higher endogenous expression in metastatic M12 
 Quantitative real-time PCR (qRT-PCR) was performed to confirm the preliminary 
microarray screening data, which showed an up regulation of miR-155 in the M12 cell 
line. qRT-PCR permits the accurate detection and quantification of endogenous levels of 
mature miR-155 in the parental P69, metastatic M12, and non-metastatic F6 variant cell 
lines using a specific fluorescent Taqman probe and primers specific for miR-155.  The 
M12 cell line had an approximate 10-fold higher miR-155 expression compared to F6 
and a 17-fold higher expression compared to P69 (Figure 9).  Thus, miR-155 was up 
regulated in the M12 cell line to an even higher level than the initial microarray data 
demonstrated and thus, could be potentially viewed as an oncomiR. 
 
Over expression of mature miR-155 in F6 cells 
 To evaluate the potential metastatic nature of miR-155 an expression vector 
containing the mature miR-155 sequence was cloned into the F6 cell line and compared 
to M12 in subsequent experiments.  Following cloning, the ph1pa-155 vector was 
transfected into F6 cells (F6+ph1pa-155) as well as the vector alone (F6+ph1pa) to serve 
as a vector control.  After drug selection the stably transformed cells, F6+ph1pa-155 and  
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Table 2.  miRs are differentially expressed in prostate cancer sublines.  A microarray 
screen evaluating the differential expression of miRs between two prostate cancer cell 
lines, M12 (metastatic) and F6 (non-metastatic), in both 2D (in vitro) and 3D (grown 
embedded in extracellular matrix).  The Ct values below represent the raw value and 
normalized against an internal control.  The RQ value is the fold difference detected 
between the normalized M12 and F6 expression level. 
 
 
microRNA M12-2D 
Ct Value 
F6-2D Ct 
Value 
M12/F6 
2D RQ 
M12-3D 
Ct Value 
F6-3D Ct 
Value 
M12/F6 
3D RQ 
miR-155 27.9 28.9 2.0 28.0 29.2 3.6 
miR-146a 40.0 31.9 272.6 25.6 37.2 3351.8 
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Figure 9.  miR-155 is up regulated in the metastatic M12 cell line.  The endogenous 
levels of the mature miR-155 in the prostate cancer progression cell lines, P69, M12, and 
F6, was evaluated using specific Taqman qRT-PCR.  Each sample was run in four sets of 
triplicates and normalized to RNU48, with bars representing the standard error.  Italicized 
values represent fold-difference compared to P69; bold values represent fold-difference 
compared to F6. 
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F6+ph1pa, were obtained.  The mRNA level of mature miR-155 in the stably transfected 
cell lines grown in tissue culture (2D) was measured via Taqman qRT-PCR and 
compared to the endogenous levels (Figure 10).  F6+ph1pa-155 had a 20-fold higher and 
11-fold higher expression compared to P69 and F6, respectively.  Importantly, the miR-
155 expression in F6+ph1pa-155 was at a physiological level comparable to M12.  Stable 
transfectants with vector alone, F6+ph1pa, showed no significant fluctuation of miR-155 
expression compared to unaltered F6 cells. 
 The miR-155 expression in F6, M12, and F6+ph1pa-155 following their growth 
embedded (3D) in the extracellular matrix Matrigel was evaluated via specific Taqman 
qRT-PCR.  These experiments were done to determine how the addition of Matrigel, a 
cell culture substrate rich in extracellular proteins as found in stroma of the prostate 
gland, would affect miR expression.  There was a 5-fold higher expression in M12 
compared to F6, and a 3-fold higher expression in F6+ph1pa-155 compared to F6 (Figure 
11).  Although the miR level was higher in 3D for F6, M12, and F6+ph1pa-155 
compared to 2D, the fold difference was considerably lower.  These results suggest the 
extracellular environment is having an effect on miR gene expression. 
 
Cell proliferation assay investigating affects of miR-155  
  To determine if miR-155 had an effect on growth, a cell proliferation assay was 
performed on F6, M12, F6+ph1pa-155, and F6+ph1pa by applying the WST-1 Reagent.   
WST-1 measures the metabolic activity of cells through the conversion of WST-1 into a 
soluble formazan salt, producing a color change in the media, which directly correlates  
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Figure 10.  Stable expression of miR 155 in F6 cells was comparable to M12 
expression level.  The over expression of mature miR-155 in F6+ph1pa-155 was 
confirmed by specific Taqman qRT-PCR.  In all cases, four separate samples were run in 
triplicate and normalized to the internal control RNU48, with bars representing standard 
error.  Italicized values represent fold-difference compared to P69; bold values represent 
fold-difference compared to F6. 
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Figure 11.  miR-155 is up regulated in M12 and F6+ph1pa-155 when grown in 
extracellular matrix.  M12 and F6+ph1pa-155 miR-155 expression was compared to F6 
when grown embedded in extracellular matrix (3D).  Three separate 3D samples of each 
cell line were run in triplicates and normalized to the internal control RNU48, with bars 
representing standard error.  Bold values represent fold-difference compared to F6. 
63 
with the cell number.  The color change was evaluated using an ELISA plate reader at 
450nm.   
A comparison of the linear trendline positive slope (0.563 and 0.633) between 
M12 and F6+ph1pa-155, respectively, showed similar proliferation rates.  Likewise, F6 
and F6+ph1pa displayed similar proliferation rates with a positive slope of 0.268 and 
0.312, respectively.  F6 and F6+ph1pa had substantially slower growth than M12 and 
F6+ph1pa-155 (Figure 12).  M12 and F6+ph1pa-155 began to plateau between day 10 
and 12 as the cells reached 100% confluency.  F6 and F6+ph1pa continued to proliferate 
for twelve days (length of assay).  It would be suspected to see a plateau in proliferation 
of F6 and F6+ph1pa cells at the same WST-1 absorbance level of M12 and F6+ph1pa-
155 cells if the assay was carried out for a longer period of time. This would reflect the 
extended time it would take the slower proliferating cells to reach confluency.  More 
importantly, F6 cells over expressing miR-155 proliferated at a rate similar to the 
metastatic M12 subline.  
 
miR-155 affects the motility and invasiveness of F6 cells 
 The motility of M12, F6, F6+ph1pa-155, and F6+ph1pa was evaluated using a 
dual chamber system (Figure 13).  Each cell line (2.5x10
4
 cells) was plated in serum 
starved media and placed into the upper chamber on top of a Transwell filter insert with 
serum rich, EGF-contiaing media, serving as a chemoattractant, placed in the lower 
chamber.  Cells were incubated for 48hr, fixed, stained, mounted on glass microscope 
slides, and counted in five random fields per filter at 400X magnification.  The motility  
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Cell Line Linear Trendline 
M12 Y= 0.563x - 1.021 
F6+ph1pa-155 Y= 0.633x - 1.137 
F6 Y= 0.268x - 0.437 
F6+ph1pha Y= 0.312x - 0.569 
 
 
Figure 12.  miR-155 over expression affects the proliferation of F6.  The cell 
proliferation of M12, F6, F6+ph1pa-155, and F6+ph1pa was observed over twelve days 
by measuring the WST-1 absorbance at 450nm.  Each cell line had eight samples 
analyzed per assay and normalized to wells without cells (blank), with bars representing 
standard error.   
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Figure 13.  Over expression of miR-155 affects the motility and invasiveness of the 
F6 subline.  (A) F6, M12, F6+ph1pa-155, and F6+ph1pa cells were plated in the upper 
chamber of a Transwell insert, subjected to chemoattractants in the lower chamber, and 
then allowed to migrate for 48h.  5 random fields per filter (thirty in total) at 400X 
magnification were counted. Bars represent standard error.  (B) F6, M12, F6+ph1pa-155, 
and F6+ph1pa were plated on top of  Matrigel-coated Transwell inserts, subjected to 
chemoattractants in the lower chamber, allowed to migrate for 48h, and evaluated as in 
panel A, with bars representing standard error.  Bold values represent fold-difference 
compared to F6. 
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of M12 and F6+ph1pa-155 was comparable, with an average of 113.8 and 110.5 
migratory cells per field, respectively.  Likewise, F6 and F6+ph1pa were comparable 
with 31.7 and 22.5 average cells per field, respectively.  More importantly, F6+ph1pa-
155 cells were approximately 3-fold more migratory than the parental F6 subline and 
matched the enhanced motility of the highly tumorigenic M12 subline (Figure 13A.). 
 The invasiveness of M12, F6, F6+ph1pa-155, and F6+ph1pa was evaluated using 
the same dual chamber system described above, but with cells plated on top of a Matrigel 
coated Transwell filter.  The ability of cells to invade the matrigel layer and attach to the 
bottom of the filter measures invasiveness.  F6 and F6+ph1pa were nearly non-invasive, 
averaging only 0.4 invading cells per field, whereas M12 and F6+ph1pa-155 had 155.6 
and 151.5 invading cells per field (Figure 13B.).  M12 and F6+ph1pa-155 were not only 
more invasive than F6 and F6+ph1pa, but more cells moved in the presence of a Matrigel 
barrier compared to a filter alone in the migration assay.  This is a strong representation 
of the possible enhanced metastatic behavior of these cells in vivo since Matrigel mimics 
the microenvironment of the prostate gland. 
 
miR-155 affects expression of sensor constructs containing putative 3’UTR targets 
 miRs exert their biological affect by down regulating mRNA through degradation 
or translation repression of target mRNAs. By either method, the end result  
is a decrease in the amount of protein for that specific mRNA target. For example, if a 
cell has a high miR level, it would be expected to show lower protein levels coming from 
its target mRNA.  Conversely, if a cell has a low miR level, it should have high protein 
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levels.  To determine if the differential expression of miR-155 contributes to the 
regulation of protein expression, luciferase assays were conducted using a plasmid 
containing the putative 3’-UTR target sequence fused to the luciferase cDNA under 
control of a ubiquitous promoter.  Three putative 3’-UTR targets, BACH1, c-Fos, and c-
maf, were chosen based on matches provided by multiple online miR-target databases 
(TargetScan, PicTar, and Miranda) and confirmed by reports the in literature (36, 37).  
An approximate 3-fold lower reporter activity was detected for luciferase fused to 
BACH1’s 3’-UTR target sequence in F6 cells over expressing miR-155 and parental 
M12, compared to F6 and F6+ph1pa (Figure 14A.).  Similar luciferase sensor constructs 
containing the 3’-UTR from c-Fos showed an approximate 3-fold and 2-fold decrease in 
luciferase activity in M12 and F6+ph1pa-155, respectively, compared to F6 and 
F6+ph1pa (Figure 14B).  The c-maf luciferase sensor construct depicted a 3.4-fold and 2-
fold decrease in luciferase activity in M12 and F6+ph1pa-155, respectively, compared to 
F6 and F6+ph1pa (Figure 14C.).  From these results it was concluded that the over 
expression of miR-155 in F6 does indeed exert a biological effect on sensor construct 
protein levels in these prostate cancer cell line variants.   
 
miR-155 regulates the expression of endogenous BACH1 protein levels 
 As seen in the qRT-PCR results, miR-155 was selectively down regulated in the 
non-metastatic prostate cancer cell line and up-regulated in the metastatic cell line.  Also, 
the luciferase sensor construct showed a down regulation of BACH1 luciferase activity in 
M12 and F6+ph1pa-155 compared to F6.  To determine if miR-155 was involved in the  
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Figure 14.  The expression of putative miR-155 targets is down regulated in M12 
and F6+ph1pa-155.  (A) BACH1 sensor activity. (B) c-Fos sensor activity. (C) c-maf 
sensor activity.  Each sample was run in one set of triplicates.  Each bar represents 
standard error.  Bold values represent fold-difference compared to F6. 
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repression of endogenous BACH1, BACH1 protein levels were evaluated in whole cell 
extracts from three different cell lines, which differed in their degree of miR-155 
expression.  As expected, cell lines which had more miR-155, such as M12 and 
F6+ph1pa-155, had decreased endogenous BACH1 levels, whereas the cell line with less 
miR-155 (F6) had increased BACH1 levels (Figure 15).  GAPDH served as a loading 
control.  It is still apparent that more BACH1 was detected in the F6 subline expressing 
the least amount of miR-155.  Thus, miR-155 expression is affecting the level of protein 
expression from both transfected sensor constructs as well as endogenous protein levels. 
 
miR-155 expression alters the morphological structures of F6 cells 
 Previously, it was determined that the M12 and F6 sublines display distinct 
differences in morphology when cultured embedded in Matrigel (3D) that correlates with 
their differences in tumorigenic/metastatic behavior in vivo (X. Zhang, unpublished 
observations).  To determine if miR-155 expression has an affect on the morphology of 
the F6 cell line, light microscope analysis of F6+ph1pa-155, M12, and F6 structures were 
conducted after twelve days of growth embedded in Matrigel.  Visual observations 
showed that F6 cells formed balls-of-cells, without projections or obvious spreading 
throughout the Matrigel (Figure 16).  The M12 subline showed large collections of cells 
with obvious cellular extensions between clusters (see arrows), which correlates with 
their enhanced growth and movement throughout Matrigel.  F6+ph1pa-155 showed large 
balls-of-cells like F6, but with extensions between cells like M12 (see arrows).  Thus, the 
addition of miR-155 does alter the morphology of the F6 cell line. 
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Figure 15.  BACH1 expression is repressed in cell lines with high levels of miR-155.  
(A) Preliminary western blot evaluating BACH1 levels in P69, F6, M12, F6+ph1pa-155, 
and F6+ph1pa.  (B) Western blot evaluating BACH1 protein levels in F6, M12, and 
F6+ph1pa-155.  Western blot analyses of whole cell protein extracts (60µg) analyzed via 
4-20% SDS polyacrylamide gel electrophoresis.  BACH1 was diluted 1:500 and GAPDH 
is included as a loading control (1:10,000 dilution). 
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Figure 16.  Expression of miR-155 in F6 alters morphology in 3D. Light microscope 
pictures of F6, M12, and F6+ph1pa-155 after 12 days of growth embedded (3D) in 
Matrigel.  F6 shows many individual ball-of-cells without extensions to other cellular 
groups.  M12 shows distinct projections away from the central accumulation of cells to 
neighboring groups of cells (see arrows in M12).  F6 cells with miR-155 over expression 
show many individual ball-of-cells like F6, but also show extensions between groups of 
cells (see arrows in F6+ph1pa-155). 
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Immunoflourescent staining investigates the morphology of F6+ph1pa-155  
 A Z-stack shows sequential images through an F6+ph1pa-155 structure.  The 
nuclei (blue) showed cells were located throughout the ball-of-cells without evidence of a 
true lumen, reflecting what is defined as a spheroid (Figure 17A-L).  In addition, there is 
an extension between the two individual spheroids (note arrows in Figure 17J), which 
may represent the ability of the cells to reach out and move, like M12.  Interestingly, the 
spheroid in the right upper corner of the Z-stack images showed a small inner mass of 
cells in the center of the spheroid.  Acini formation is thought to occur through apoptosis 
of such inner masses of cells, resulting in a hollow lumen.  It appears that this spheroid 
might be attempting such a process, but incompletely.  This was an interesting, but 
isolated observation. 
Further evaluation of 3D morphological structures in F6+ph1pa-155 cells 
following growth embedded in Matrigel was needed to establish internal structure and 
potential polarity of cellular adhesion proteins.  F6+ph1pa-155 structures were stained  
with antibodies to vimentin, β-catenin, and α6-, β1- and β4-integrins (Figure 18A-D.).  
Figure 18A showed F6 structures exhibiting some polarity with definite co-localization of 
α6- and β4-integrins at the plasma membrane as confirmed on the merged image.  M12s 
showed co-localization, but no polarity of the integrin pair, whereas F6+ph1pa-155 
showed co-localization and intermediate polarity of both integrins.  Figure 18B showed 
similar results as Figure 18A.  Figure 18C depicts β-catenin staining, which is basolateral 
in F6 structures, but associated with the membrane outlining each cell in the cluster of  
73 
 
 
Figure 17.  F6+ph1pa-155 form solid spheroids without a lumen.  An image at every 
third plane from a Z-stack of F6+ph1pa-155 shows the nuclei (blue) forming two solid 
spheroids, with cells extending between then (arrows in panel j.).  In panels d-i.the upper 
right spheroid shows a layer of cells surrounding a center cluster of cells, but no true 
lumen is present.  Panels g-l., show the lower left spheroid completely void of lumen.  A 
measurement of 5µm is on the lower right of each panel. 
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Figure 18A.  Expression of miR-155 in F6 altered morphological structures. α6-
integrin (green), β4-integrin (red), and merged are stained as indicated. A measurement 
of 5µm is on the lower right of each panel. 
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Figure 18B.  Expression of miR-155 in F6 altered morphological structures. α6-
integrin (green), β1-integrin (red), and merged image are stained as indicated. A 
measurement of 5µm is on the lower right of each panel.
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Figure 18C.  Expression of miR-155 in F6 altered morphological structures. β-
catenin (red) is stained as indicated. A measurement of 5µm is on the lower right of each 
panel. 
 
 
 
 
Figure 18D.  Expression of miR-155 in F6 altered morphological structures.  
Immunoflourescent staining comparing the morphological structures between F6, M12, 
and F6+miR155. (D)Vimentin (green) is stained as indicated. A measurement of 5µm is 
on the lower right of each panel. 
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M12 and F6+ph1pa-155 cells.  Finally, Figure 18D depicts the staining of vimentin, 
which is absent in F6 structures and present in both M12 and F6+ph1pa-155 structures. 
 
miR-155 affects the morphological size of F6 structures grown in 3D 
 A comparison between P69, F6, and F6+ph1pa-155 was performed to evaluate the 
affect of miR-155 on the size of spheroid growth.  Zhang et al. (unpublished results) 
determined the acini diameter of P69 and F6 structures grown in 3D from day 3 through 
15.  The diameter of the solid spheroids formed by the F6+ph1pa-155 cell line grown in 
3D was compared to the positive slope of P69 and F6 at two stages of growth, day 6 and 
day 12 (Figure 19).  At day 6, the diameter of the F6+ph1pa-155 spheroid was double 
that of P69 and F6 acini, 61µm compared to 32 µm and 30 µm, respectively.  At day 12, 
the F6+ph1pa-155 spheroids were just under double the diameter of P69 and F6 acini, 
111µm compared to 64µm and 60µm, respectively.  The diameter of M12 structures was 
undeterminable because these M12 do not form acini or even a solid sphere of cells when 
grown in 3D (see Figure 17).   
 
Mature miR-146a mRNA levels are up regulated in metastatic M12  
 The initial microarray screen suggested miR-146a might be a potential oncomiR 
when comparing the two prostate cancer cell lines, M12 to F6.  To determine the 
endogenous levels of mature miR-146a, a specific Taqman qRT-PCR was performed on 
P69, M12, and F6 (Figure 20).  It was found that miR-146a had a 9.9-fold higher 
expression level in M12 compared to P69 and a 7.0-fold higher expression between M12  
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Figure 19.  miR-155 increases the diameter of F6 cells.  The diameter of P69 and F6 
acini was quantitated and compared to the diameter of F6+ph1pa-155 spheroids at day 6 
and 12 when grown in Matrigel (3D).   
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Figure 20.  mir-146a is up regulated in metastatic M12 cell line.  The endogenous 
expression of the mature form of miR-146a is up regulated in M12 compared to P69 and 
F6.  Four samples of each cell line was evaluated in triplicates, and normalized to an 
internal control, RNU48.  Each bar represents the standard error.  Italicized values 
represent fold-difference compared to P69; bold values represent fold-difference 
compared to F6. 
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 and F6.  These observations confirm data from the initial microarray screen, but at a 
lower fold difference. 
 
Over expression of miR-146a in F6 cells  
 To determine the affect of miR-146a over expression on F6 cell behavior, the 
precursor sequence was cloned into pSiren-RetroQ vector and F6 stably transformed cells 
were constructed as described in Materials and Methods.  In addition, a non-targeting 
sequence was also inserted into the vector, serving as a control (pSiren-NTC).  
Determining the mature miR-146a level in stably transfected F6 cells was performed 
using specific Taqman primers and qRT-PCR.  F6+pSiren-146a had a 195-fold higher 
expression compared to F6, a 272-fold higher expression compared to P69, and a 28-fold 
higher expression compared to M12.  F6+pSiren-NTC had no increase in mature miR-
146a levels (Figure 21). 
To evaluate the affect of the microenvironment on the expression of mature miR-
146a levels, M12, F6, and F6+pSiren-146a cells were grown embedded in Matrigel and 
assayed using the specific Taqman qRT-PCR (Figure 22).  Comparison of miR-146a in 
M12 and F6+pSiren-146a 3D showed a 353-fold and 911-fold higher expression 
compared to F6, and a 2.6-fold higher expression in F6+pSiren-146 compared to M12.  
Although the extracellular environment enhanced the miR-146a level in M12 3D 
compared to 2D (2.4-fold increase), a decrease in F6 3D compared to 2D (21-fold 
decrease) and a decrease in F6+pSiren-146a 3D compared to 2D (4.5-fold decrease) was 
also seen.  Thus, the microenvironment of Matrigel is exerting an effect on specific miR 
expression.
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Figure 21.  miR-146a is over expressed in the stably transformed F6+pSiren-146a 
cell line.  Following the stable transfection of miR-146a into F6, mature miR-146a levels 
were evaluated using specific Taqman qRT-PCR.  Four samples from each cell line were 
evaluated in triplicate and normalized to the internal control, RNU48.  Bars represent the 
standard error.  Italicized values represent fold-difference compared to P69; bold values 
represent fold-difference compared to F6. 
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Figure 22.  miR-146a is up regulated in M12 and F6+pSiren-146a grown in 3D.  
miR-146a is up regulated in M12 and F6+miR-146a when grown embedded in Matrigel, 
compared to F6.  Two samples from each cell line were evaluated in triplicate, and 
normalized to an internal control, RNU48.  Each bar represents the standard error.  Bold 
values represent fold-difference compared to F6. 
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miR-146a affects the growth of F6 cells 
 The affect of miR-146a on the growth of M12, F6, F6+pSiren-146a, and 
F6+pSiren-NTC cells was monitored over twelve days using the WST-1 proliferation 
reagent.   The positive slopes derived by linear trendline showed M12 and F6+pSiren-
146a cells proliferated at the same rate, 0.529 and 0.563, respectively.  Likewise, F6 and 
F6+pSiren-NTC proliferated at similar rates, 0.268 and 0.275, respectively.  Based on the 
positive slopes, M12 and F6+pSiren-146a had increased proliferation rates compared to 
F6 and F6+pSiren-NTC (Figure 23). 
 
miR-146a affects the motility and invasiveness of F6 cells 
 A dual chamber system was used to determine the affect of miR-146a on motility 
and invasion of F6 cells.  M12, F6, F6+pSiren-146a, and F6+pSiren-NTC cells were 
plated in the upper chamber of a Transwell insert in serum starved media, with 
chemoattractant media placed in the lower chamber.  M12 was 3.6-times more motile 
than F6 (113.8 cells per field compared to 31.7 cells) and F6+pSiren-146a 2.7-times more 
motile than F6 (86.7 cells per field compared to 31.7 cells), but F6+pSiren-146a was only 
0.75-times as motile as M12 (Figure 24A).  Thus, the over expression of miR-146a is 
having some effect on the motility of F6 cells.  The invasiveness of cells was evaluated 
using the same dual chamber system, but with cells placed on top of a Matrigel coated 
Transwell insert, as mentioned in Methods and Materials.  M12 cells were the most 
invasive, with 155.6 cells per field, a 389-fold difference compared to F6 cells (0.4 cells 
per field).  F6+pSiren-146a was also invasive, but not to the extent of M12, with only 
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Cell Line Linear Trendline 
M12 Y= 0.529x - 0.775 
F6+pSiren-146a Y= 0.563x - 1.021 
F6 Y= 0.268x - 0.437 
F6+pSiren-NTC Y= 0.275x - 0.479 
 
 
Figure 23.  miR-146a affects the cell proliferation of F6.  The proliferation of M12, 
F6, F6+pSiren-146a, and F6+pSiren-NTC cells was observed over twelve days by 
measuring the WST-1 absorbance at 450nm.  Each cell line had eight samples read per 
assay and was normalized to wells without cells (blank). Bars represent the standard 
error.   
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Figure 24. miR-146a affects the motility and invasiveness of F6.  (A) F6, M12, 
F6+pSiren-146a, and F6+pSiren-NTC cells were plated in the upper chamber of a 
Transwell insert, subjected to chemoattractants in the lower chamber, and then allowed to 
migrate for 48h.  Migrated cells were fixed, stained, and counted in 5 random fields per 
filter (thirty in total) at 400X magnification. Bars represents the standard error. (B) F6, 
M12, F6+pSiren-146a, and F6+pSiren-NTC were plated on Matrigel-coated Transwell 
inserts, subjected to chemoattractants in the lower chamber, and then allowed to migrate 
for 48h.  Migrated cells were fixed, stained, and counted in 5 random fields per filter 
(thirty in total) at 400X magnification. Bars represent the standard error.  Bold values 
represent fold-difference compared to F6. 
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103.1 cells per field, a 257-fold difference compared to F6 cells.  The control vector, 
F6+pSiren-NTC was comparable to F6 with 0.9 cells per field compared to 0.4 cells per 
field, respectively (Figure 24B).  In the presence of Matrigel, the highly motile cells 
(M12 and F6+pSiren-146a) became more invasive, and the less motile cells became 
nearly non-invasive. 
 
miR-146a elicits an effect on TRAF6 
 To demonstrate that miR-146a affects the protein level of a target mRNA, a 
luciferase sensor construct was evaluated.  TRAF6 3’-UTR was proposed to be a  
miR-146a target via a screen of the miR sequence target databases (TargetScan, PicTar, 
Miranda) and confirmed experimentally (19).  M12 had a slightly lower luciferase 
activity value, 35, compared to F6, 38.  F6+pSiren-146a over expressing 146a drove 
down TRAF6 luciferase activity level to 27 (Figure 25).  Although the relative TRAF6 
luciferase level was not down regulated to a significant level in M12, the over expression 
of miR-146a in F6 (having 27.6 times more miR-146a than M12) did decrease TRAF6 
and concurs that TRAF6 is a target for miR-146a.  
 
Immunoflourescent staining depicts the morphological structure of F6+pSiren-146a 
grown in 3D 
In order to evaluate the affect of miR-146a on the internal composition of the F6 
subline, a Z-stack was performed on an F6+pSiren-146a ball-of-cells structure grown in 
3D.  Sequential images of every third plane were obtained, showing the nuclei (blue) of  
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Figure 25. miR-146a affects TRAF6.  TRAF6 3’UTR was transiently transfected into 
F6, M12, and F6+pSiren-146a cells and luciferase activity measured as described in 
Material and Methods.  Reporter gene firefly activity was normalized to internal renilla, 
serving as an internal control.  Results are the average of one set of triplicates and bars 
represent the standard error.  Bold values represent fold-difference compared to F6. 
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cells located throughout the entire structure, with no evidence of a lumen (Figure 26).  
This reflects a solid spheroid structure.  Therefore, miR-146a does affect the 
morphological structure of the F6 cell line when grown in 3D. 
 
miR-146a affects the morphological size of F6 structures when grown in 3D 
 To evaluate the affect of miR-146a on F6 cells, P69, F6, and F6+pSiren-146a 
structures were compared when cells were grown in 3D.  Zhang et al. (unpublished data) 
previously determined the diameter of P69 and F6 structures grown in 3D from day 3 
through 15.  The diameter of F6+pSiren-146a structures grown in 3D was compared to 
the positive slope of the plotted acini diameters of P69 and F6 at two stages of growth, 
day 6 and day 12.  At day 6 F6+pSiren-146a had a diameter of 20.7µm, 0.33 times 
smaller than P69 and F6.  Visual observations of F6-pSiren-146a cells showed little 
structure formation at day 6.  At day 12, F6+pSiren-146a cells were well structured with 
a diameter of 123.8µm, 2 times higher than P69 and F6 (Figure 27).  Thus, miR-146a 
expression does increase the diameter of F6 structures grown in 3D.  
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Figure 26.  F6+pSiren-146a form solid spheroids without a lumen. A-J. Show an 
image at every third plane from a Z-stack of F6+pSiren-146a.  The staining of α6-integrin 
(green) and the nuclei (blue) show formation of a solid spheroid without a lumen.  A 
measurement of 5µm is on the lower right of each panel. 
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Figure 27. miR-146a increases the diameter of structures formed by the F6 subline 
grown in 3D.  Following growth in 3D, the diameter of P69 and F6 acini were 
quantitated and compared to the diameter of F6+pSiren-146a spheroids at day 6 and 12.  
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DISCUSSION 
 
microRNAs are found to be both up regulated and down regulated in cancer.  A 
microarray analysis found two potential up regulated oncomiRs in a prostate cancer 
progression model.  qRT-PCR further confirmed that miR-155 and miR-146a were 
indeed up regulated in the metastatic M12 cell line compared to its non-metastatic and 
barely tumorigenic variant, F6.  The affect miR-155 and miR-146a had on prostate cancer 
cells was evaluated through stable over expression into the F6 cell line and compared to 
M12.  It was shown that over expression of both miRs does increase cell growth, motility, 
invasiveness, and affects cellular morphology. 
The qRT-PCR measurements of miR-155 expression in the stably transfected F6 
subline grown in 2D indicate that miR-155 is expressed at levels comparable to M12.  
The miR-155 levels in 3D showed an up regulation of miR-155 in F6, M12, and 
F6+ph1pa-155 above those levels found in 2D; however, when grown embedded in 
Matrigel the F6+ph1pa-155 cell line expressed miR-155 at one-half the level exhibited by 
the M12 cell line.  This result suggests the presence of extracellular matrix is controlling 
miR gene expression.  Since Matrigel mimics the host’s extracellular environment, the F6 
versus M12 miR-155 levels detected in 3D might be a more accurate representation of the 
level of miR gene expression in human prostate cancer cells.  In other words, the 
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microenvironment may be influencing the F6+ph1pa-155 cells to down regulate miR-155 
expression in attempts to maintain their non-metastatic “F6” behavior.  The morphology 
of the cellular structures grown in 3D supports this hypothesis.  The morphology of 
F6+ph1pa-155 is intermediate to the characteristics displayed by the highly metastatic 
M12 subline versus the weakly tumorigenic, non-metastatic F6 subline.  Unpublished 
data from Zhang et al. showed F6 structures having an organized and polarized acini 
structure with a definite lumen.  F6+ph1pa-155 cells also show an organized collection of 
cells, but they do not exhibit a lumen.  Instead they form a solid spheroid of cells.  They 
also have display an intermediate polarization of integrins, much like F6, but with 
cellular extensions between spheroids, like the M12 cells.  In addition, the positive 
staining of vimentin in F6+ph1pa-155 and M12 cell lines, but none in the F6 subline, 
further indicates that the F6+ph1pa-155 subline is showing some tumorigenic 
characteristics of the M12 subline. Vimentin is a known marker for mesenchymal cells 
and depicts cells that have transgressed through an epithelial-mesenchymal transition, 
EMT (15). Moreover, in most cancers like breast, vimentin expression is indicative of 
poorly differentiated, highly metastatic tumor cells with poor prognosis (50).  
Interestingly, here vimentin is expressed by both the metastatic M12 and F6+ph1pa-155 
sublines, but not the parental F6 or F6+ph1pa sublines suggesting the progression of 
these cells to a more tumorigenic/metastatic state by the restoration of miR155 
expression.  How miR-155 expression might be regulating vimentin expression is 
presently unknown. 
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 MicroRNAs target the 3’UTR of mRNA through perfect or imperfect matching 
and down regulate their expression by either degradation or translational repression, 
respectively.  Evaluation of three miR-155 targets, BACH1, c-Fos, and c-maf, confirmed 
that they were targets of miR-155.  All three targets showed relatively high luciferase 
activity in F6 and F6+ph1pa, but were down regulated in M12 and F6+ph1pa-155 
sublines.  These results agree with the paradigm that high miR levels cause translational 
repression of a target mRNA and low miR levels permit protein expression.  More 
importantly the ph1pa vector is not having an effect on these targets, but rather the effect 
is due to expression of the particular miR.  BACH1 appears to be the best target for miR-
155 because the over expressing F6 cell line resulted in BACH1 levels reduced to a 
physiological comparable level to that exhibited by the M12 subline.  The vector only F6 
cell line had levels comparable to F6.  BACH1 is a helicase involved in double stranded 
DNA repair, and its down regulation in the M12 cell line could allow for the 
accumulation of DNA breaks and mutations, pushing these cells towards a more 
tumorigenic behavior.  Thus, BACH1 could be a major player in the tumor progression of 
the M12 cell line.   
 In addition, c-Fos and c-maf sensor constructs both showed decreased expression 
in M12 compared to F6, with intermediate down regulated expressions in F6+ph1pa-155.  
Like in BACH1, the empty vector and F6 had comparable levels.  The repression of c-
maf might also contribute to oncogenesis.  Recently it has been shown that the c-maf 
transcription factor induces the expression of the tumor suppressor p53 (44). The p69, 
M12 and F6 cell lines are known to contain wild-type p53 (personnel communication, 
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Joy Ware). Thus, an increase in miR-155 would cause a decrease in c-maf, leading to 
decreased levels of the p53 tumor suppressor, allowing cells to push towards unmitigated 
growth and oncogenesis.  It is unclear at this stage why decreased levels of c-Fos would 
be beneficial to the metastatic M12 cell line.  c-Fos is a well known and described proto-
oncogene that has been experimentally confirmed to have high mRNA expression levels 
in prostate cancer compared to BPH (51).  Therefore, M12 having high miR-155 levels 
would target the proto-oncogene and decrease c-Fos expression, as confirmed in Figure 
14C.  A decrease in the proto-oncogene would theoretically mean oncogenesis would be 
halted.  c-Fos is not only a proto-oncogene, but is one of many transcription factors that 
dimerize with Jun family members, allowing for gene expression (51). However, Western 
blot analysis showed that none of these cell lines, p69, M12, F6, F6+ph1pa-155 or F6 
plus vector only, are normally expressing measurable amounts of c-fos protein.  It is 
assumed that the addition of a stress modulater such as phorbol ester (TPA) would induce 
c-fos expression in these cell lines and this induction would be eliminated by over 
expression of miR-155 in the F6+ph1pa cells as has been shown in other cell lines and 
supported here by c-fos luciferase sensor construct activity (52). In these cell lines, c-fos 
is not being expressed and thus normally would not be playing a role in tumor 
progression under these conditions.   
The evaluation of miR-155 targets in the over expressing F6 cell line (F6+ph1pa-
155) show BACH1 to be the most repressed target out of the three putative targets 
analyzed here.  As mentioned in the introduction, the function of miRs to repress 
translation is directly correlated to the match between the 5’seed sequence of the mature 
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miR to its mRNA 3’UTR target.  Presumably, a complete match between the mRNA seed 
sequence, nucleotides 2-8 (5’ to 3’ on the mature miR), is required to target a miR to a 
particular message. However, additional matches between the miR and its target would 
aid in both the selection and stability of this interaction. As shown in Figure 5A, the 
BACH1 3’UTR has two functional binding sites for miR-155 at seed position nucleotide 
2-8.  The c-Fos 3’UTR (Figure 5B) shows only one binding site (at seed nucleotides 2-6 
and 8) for miR-155 targeting. Figure 5C shows three regions on the c-maf 3’UTR that 
miR-155 could target.  miR-155 matches to the seed region of the three c-maf 3’UTR 
sequences at nucleotides 2-7, 2-6 and 8, and 2-7.  Simply comparing the matches in the 
seed region between miR-155 and the target mRNA does not reveal an answer as to why 
BACH1 is more repressed in F6+ph1pa-155, compared to c-Fos and c-maf.  An 
examination of the sequence match between the 3’-region of miR-155 and the 5’-region 
of c-Fos and c-maf, (i.e., base matches outside the seed sequence recognition region) 
reveals little matching even when invoking base pair wobble. Conversely, the 3’-region 
of miR-155 and the 5’-region of BACH1 show at least five base matches, which 
represent canonical miRNA:mRNA interaction as previously mentioned in the 
introduction. Canonical interaction, one of the three proposed base-pairing mechanisms 
miRs use for recognition of a target mRNA, is the binding interaction of the 5’- and 3’-
end of the miRNA.   Thus, BACH1 may potentially represent stronger binding, by having 
two specific and important binding sites, which exhibit a more favorable negative energy 
of binding between the miR and its target mRNA.  
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 Investigation of BACH1 protein levels independent of a reporter system was 
analyzed via a Western blot.  Multiple blots were performed at different protein 
concentrations and antibody dilutions.  Previous blots not depicted showed protein 
loading to be unequal.  The band densities of GAPDH were evaluated using BioRad 
Quantity One 4.4.0 application and normalized to each other in order to correct for the 
unequal protein load.  The antibody provided by Zymed produced many contaminating 
bands, one of which fell very close to the GAPDH loading control band, and the densities 
were skewed based on this contaminating band.  Therefore, when the Western blot was 
performed the nitrocellulose membrane was cut at the 50kDa band, allowing for 
independent antibody incubations and thus avoiding the contaminating band depleting the 
levels of BACH 1 antibody.  Unfortunately, determining that the contaminating band was 
in fact skewing the loading control band was not observed until after the Western blot 
depicted in Figure 15A was performed.  The blot in Figure 15A does show protein 
loading disparities, but it is important to include for it shows a large amount of BACH1 
protein in F6 compared to M12, with a much lower GAPDH protein concentration in F6 
compared to M12.  In addition, the vector only cell line showed BACH1 present.  It is 
inconclusive at this time to determine if miR-155 in the F6+ph1pa-155 cell line is having 
the same affect on BACH1 as M12 due to the protein loading error.  An additional 
western blot was performed, Figure 15B, and depicts high levels of BACH1 in F6 with 
decreased levels in M12 and F6+ph1pa-155, much like the original blot but with equal 
protein loading. 
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 Similar to the miR-155 results, miR-146a was shown to be up regulated in the 
metastatic M12 cell line compared to barely tumorigenic and non-metastatic F6 subline in 
the initial microarray screen.  Confirmation of the differential expression was evaluated 
through qRT-PCR in P69, F6 and M12 cell lines, confirming that miR-146a was up 
regulated in M12 compared to P69 and F6.  The potential role of miR-146a in tumor 
progression was evaluated through the over expression of miR-146a in the F6 subline.  
qRT-PCR results confirmed that miR-146a was being over expressed in the stable 
transformant, but at much higher and incomparable levels compared to M12.  However, 
the F6 plus vector only was at levels comparable to F6 without vector, indicating that the 
vector alone was not exhibiting an effect on miR-146a expression.  Further evaluation of 
miR-146a in F6, M12, and F6+pSiren-146a 3D samples was performed using specific 
Taqman qRT-PCR.  It was shown that miR-146a expression was suppressed in F6 cells at 
a level 21 times lower than the 2D results.  miR-146a expression was up regulated in 
M12 3D compared to 2D, noting a 15-fold increase.  Lastly, miR-146a expression was 
down regulated in F6+pSiren-146a 3D compared to 2D, noting a 4.5-fold decrease.  The 
decrease in miR expression in F6 and F6+pSiren-146 in 2D compared to 3D, again marks 
the importance of the extracellular environment and the role it may play in influencing 
gene expression.  Since F6 cells are barely tumorigenic and non-metastatic, the 
microenvironment of the extracellular matrix is influencing the cells to behave like barely 
tumorigenic and non-metastatic cells, thus decreasing the effect of a putative oncomiR.  
In addition, the decrease in miR-146a expression in F6+pSiren-146a might mark the 
microenvironment trying to influence the “F6” part of the cell transformant to remain 
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non-metastatic and barely tumorigenic.  Nonetheless, miR-146a in M12 and F6+pSiren-
146a was expressed in 3D at much higher levels compared to F6.   
 The morphological changes miR-146a may potentiate in the F6 cell line was 
evaluated by immunoflourescent staining.  A Z-stack of multiple images of a F6+pSiren-
146a structure showed the structure to be a solid spheroid of cells with the absence of a 
lumen, much like the F6+ph1pa-155 structures.  There were no cellular projections 
between spheroids as noted in F6+ph1pa-155.  The analysis of vimentin, β-catenin, and 
α6-, β1-, and β4-integrins was inconclusive due to poor antibody staining.  
 miR-146a did have an affect on the TRAF6 sensor construct, but not to levels that 
would represent TRAF6 as being a major player in tumor progression.  As noted in 
Figure 25, the expression of miR-146a in the M12 cell line did not down regulate TRAF6 
sensor construct activity to a significant fold difference.  But, the over expression of miR-
146a in the F6 transformant did indeed drive down the TRAF6 activity below that of 
M12, thus confirming TRAF6 as a miR-146a target.  Additionally, the target sequence of 
miR-146a in the 3’UTR of TRAF6 mRNA (Figure 6), had extensive homology in the 
seed regions, matching to nucleotides 2-7, even further supporting TRAF6 as a target of 
miR-146a.  The mild reduction of TRAF6 expression in M12 and F6+pSiren-146a may 
be explained by the fact that TRAF6 is an important player in immunity and immune 
cells, and the expression of TRAF6 in the prostate cancer progression model is not as 
important as its expression in other cell lines.  Thus, TRAF6 might show differential 
expression between various tissues but in the prostate gland it does not represent an 
adequate source for experimental analyses. 
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 miR-155 and miR-146 both had effects on the growth of F6 cell lines.  The cell 
proliferation of F6 transformants compared to M12, F6, and F6 with vector only, showed 
a marked increase in proliferation to levels equal and above those of M12.   The spheroid 
diameter of F6+pSiren-146a 3D structures was determined after 6 and 12 days of growth 
and compared to the previously determined acini diameters of P69 and F6.  The diameter 
size at day 12 reflects a much large cell mass and corresponds with the proliferation assay 
showing F6+pSiren-146a’s positive slope approximately twice as great as F6 or F6 with 
vector only.  Likewise, the diameter of F6+ph1pa-155 3D structures at day 6 and 12 
compared to the cell proliferation assay.   At day 6 and 12, F6+ph1pa-155 had double the 
WST-1 absorbency, which corresponds to the spheroid diameter being double that of F6 
and P69.  These results are in line with the suggestion that an increase in proliferation 
rate results in an increase in cell number, necessitating an increase in cell mass (diameter) 
of structures formed in 3D.   
 miR-155 did show an effect on the motility and invasiveness of the F6 cells lines.  
M12 and F6+ph1pa-155 were shown to have similar motility and invasive properties 
(Figure 12).  Although F6 and F6+ph1pa also had similar motility and invasive properties 
to each other, they were considerably much lower than M12 and F6+ph1pa-155.  More 
importantly the vector had no effect.  The average number of M12 and F6+ph1pa-155 
cells able to move through the Matrigel layer was higher than the motility of cells 
cultured in the absence of Matrigel layer (1.4-fold increase).  The average number of F6 
and F6+ph1pa cells able to move through the Matrigel were considerably reduced in the 
absence of Matrigel layer (80-fold reduction).  Likewise, miR-146a showed an effect on 
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motility and invasiveness in the F6 cells, but to a lesser extent compared to miR-155.  
M12 and F6+pSiren-146 were 3- and 4-fold more motile compared to F6 and F6+pSiren-
NTC, respectively.  M12 and F6+pSiren-146a were 389- and 113-fold more invasive 
compared to F6 and F6+pSiren-NTC.  Like in the case of cells over expressing miR-155, 
cells over expressing miR-146a (M12 and F6+pSiren-146a) have an increase in 
invasiveness compared to motile cells when placed on Matrigel.  In addition, F6 and 
F6+pSiren-NTC markedly decrease their motility in the presence of Matrigel, going from 
31.7 and 16.6 motile cells, respectively, in the presence of the filter only to 0.4 and 0.9 
cells, respectively, in the presence Matrigel on the filter.  This marks a 79-fold decrease 
in cellular movement in F6 cells subjected to the microenvironment of extracellular 
matrices and an 18-fold decrease in F6+pSiren-NTC.  These comparisons between 
motility and invasiveness for both miR-155 and miR-146a show that the 
microenvironment might act as a chemoattractant for motile cells and amplify their 
metastatic and invasive behaviors, whereas blocking invasiveness of less motile cells.  
This finding is in agreement with the results Ware et al. found, that M12 cells were 
metastatic and F6 cells were non-metastatic (14, 15).  An invasive behavior in vitro might 
correspond to a metastatic behavior in vivo.  In summary, miR-155 and miR-146a 
exhibited an effect on putative targets, increased cellular growth, motility, and 
invasiveness, and lastly altered the morphology of structures to those which represent 
more metastatic structures.  Thus, miR-155 and miR-146a could potentially play an 
important role in prostate tumor progression and the metastatic nature of M12 cells, 
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which now warrants further testing by subcutaneous and orthotopic injection into the 
prostate of male, athymic mice. 
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